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Abstract
Quantitative imaging biomarkers (QIBs) are increasingly being incorporated into early phase clinical
trials as a means of non-invasively assessing the spatially heterogeneous treatment response to
anticancer therapies, particularly as indicators for early response. MR QIBs are derived from the
analysis of in vivo imaging data, such as that acquired via dynamic contrast enhanced (DCE), dynamic
susceptibility enhanced (DSC), and diffusion tensor imaging (DTI). To date, preclinical and clinical
applications of such QIBs have provided strong evidence for potential efficacy, but efforts to create
meaningful estimates of localized treatment response using multiple QIBs have been stifled by the need
for rigorous characterization of biases and variances inherent in MR equipment and analysis tools and a
suitable means of associating QIB changes with treatment response. This research sought to develop
such a framework, incorporating multiple MRI QIBs associated with the microvascular environment,
e.g., permeability, flow, and volume, and the cellular environment, e.g., water diffusion, into a single
classification model to generate maps of predicted locoregional response. To ensure treatment
associated changes measured in vivo exceeded equipment related levels of bias and variance, two
phantoms were developed. Weekly assessment of the MR imaging data from which the QIBs were
derived resulted in coefficients of variation less than 15% for QIBs assessed, well below the expected
treatment related changes (approximately 40%). Bias and variance associated with the software tools
developed to facilitate longitudinal assessments of treatment response, QUATTRO, was also assessed
using synthesized imaging data mimicking clinically relevant acquisitions schema, and found to
introduce negligible levels of bias and variance. Finally, to develop an integrated approach to assessing
response using multiple QIBs, two experienced radiation oncologists contoured regions of partial
response (PR), stable disease (SD), and progressive disease (PD) on rigidly co-registered high grade
brain tumor patient data sets, which included DCE, DSC, and DTI acquisitions. Response matched voxelby-voxel QIBs were trained using an ordinal regression classifier. Using leave-one-out cross-validation,
the prediction accuracies of the best model (single DTI QIB) were found to be, mean (standard error),
69.0 (11.1)% for SD, 35.2 (11.7)% for PD, and 52.3(9.7)% overall. In summary, this work resulted in the
development of a comprehensive framework for predicting voxelwise radiological treatment response,
including the development of phantoms and associated acquisitions for MR equipment quality control
and establishment of system-related bias and variance, and a comprehensive software package for
performing related image analyses and outcome prediction.
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Chapter 1 Introduction

1.1 The Role of Quantitative Imaging Biomarkers in Treatment Assessment
Assessing treatment response in cancer patients offers a multitude of challenges. Traditional
measures of response, such as the Response Evaluation Criteria in Solid Tumors (RECIST) [1] and the
more recent Revised Assessment in Neuro-Oncology (RANO) [2], have found success in the simplicity of
required measurements, namely evaluation of tumor size. However, structural assessment as defined by
these evaluation criteria has many inherent limitations, such as image acquisition variability (especially
for two-dimensional image slices), interpreter differences, involvement of lymph nodes, and tumor
type/location to name a few, as Husband et al. [3] and Jaffe [4] point out. Resulting variability can
deleteriously impact the applicability and efficacy of response assessment. Indeed, these inadequacies
have inspired the development of specialized criteria such as the recently updated RANO [2] for
assessing high-grade gliomas or the modified RECIST assessment for hepatocellular carcinoma [5].
However, assessment of structural information may be inadequate and/or delayed significantly,
especially for novel targeted therapeutics. For example, therapies incorporating anti-angiogenic drugs
may induce substantial changes in a lesion’s vascularity, resulting in a lack or altogether absence of
enhancement patterns in the tumor (a common image feature used in the RANO assessment [2])
regardless of the actual underlying tumor response. However, the use of functional information derived
from imaging-based biological markers, or imaging biomarkers for short, such as vascular permeability
and flow, is a promising new avenue for treatment assessment.
Biomarkers, especially those potentially suitable for use as surrogate endpoints, are playing an
increasingly important role in clinical trials as a means of assessing response to novel and combined
therapeutic interventions. As defined by the Biomarkers Definitions Working Group [6], these markers
objectively characterize normal and pathological biological processes. Advancements in imaging
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technology have resulted in the availability of many image acquisition techniques capable of quantifying,
in a non- or minimally-invasive manner, various biological characteristics, a subset of markers referred
to collectively as quantitative imaging biomarkers (QIBs). Quantifiable functional information, such as
cellular proliferation, perfusion, vascular flow, volume, and permeability, cellularity, and metabolism,
comprise a subset of the class of QIBs. Techniques to quantify this information have been developed for
modalities as diverse as magnetic resonance imaging (MRI), computed tomography (CT), positron
emission tomography (PET), nuclear medicine, and ultrasound [7]. However, the myriad image contrast
mechanisms, use of non-ionizing radiation, and continual improvements in MR hardware have led to
strengthening interest in applications of functional MR QIBs. Aside from providing functional
information, some biomarkers have been shown to exhibit measureable changes predictive of tissue
response within days following the initial treatment [7-8], substantially sooner than would be detectable
by monitoring morphological changes alone. This need for rapid assessment of patient response to
novel or combined cancer therapies has motivated the incorporation of many of these MR imaging
techniques into early phase clinical trials.
The remainder of this chapter will focus on the introduction and discussion of the functional
MRI biomarkers specific to this work (i.e., diffusion, perfusion, and vascular permeability), their
biological significance and use as a means of assessing cancer therapies, challenges associated with their
incorporation into the clinical setting, and the motivation for developing multi-parametric response
maps as a means of assessing treatment response. Thorough development of the theory, acquisition,
and analysis of these biomarkers is covered in Chapter 2. Extensive discussions of QIB applications are
available from a number of authors. For example, oncologic applications of QIBs derived from contrast
enhanced MR acquisitions are discussed in the text by Jackson [10], or a more generic discussion of
diffusion-weighted imaging derived QIB applications can be found in the text by Koh and Thoeny [11].
For brain applications, the text by Tofts [12] serves as an excellent reference for commonly used MR
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imaging biomarkers in the investigation of a number of pathological processes. The reader is referred to
these texts, and other reviews [13]–[18], for a broader, more detailed perspective regarding specific
applications of QIBs.

1.2 Diffusion
Perhaps one of the most commonly investigated physical processes in the assessment of
treatment response is the molecular diffusion of water, a process of random thermal molecular motion.
In tissue, this stochastic motion of water molecules is affected by a number of biophysical mechanisms,
such as intracellular-extracellular water exchange, active transport, flow/perfusion, bulk movements,
and tortuosity (a property describing the cellular density, volume, and extracellular space organization)
[19]. Often the property of most interest in investigating observed differences in diffusion processes is
the interaction of water molecules with structures that inhibit water mobility (e.g., hydrophilic cellular
membranes and organelles within cells). In fact, differences in the microenvironments of the
intracellular and extracellular spaces give rise to unique diffusion coefficients. However, in biological
tissues, diffusion is often characterized by a single parameter describing the general mobility of water
molecules, incorporating the several aforementioned physical processes, hence the name apparent
diffusion coefficient (ADC). Diffusion-weighted imaging (DWI) is the MRI method used to quantify this
scalar quantity.
Most tissues in the human body are characterized by water diffusion rates that are equal in all
directions (isotropic diffusion), although the existence of, for example, cell membranes restricts the
ability of water molecules to freely diffuse, giving rise to the process called restricted diffusion. The
degree of restricted water diffusion is generally thought to correspond to the cellular density of tissue,
which has been confirmed by numerous researchers. A majority of studies comparing histology to ADC
measurements have shown a statistically significant (negative) correlation between the histologically
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derived cellularity and ADC values in tumors [20]–[31]. However, some investigators, for example
Sadeghi et al.[32], have found a non-significant relationship between cellular density and the ADC.
Consensus has yet to be reached regarding the exact mechanisms responsible for affecting
change in longitudinal ADC measurements during treatment regimens [19]. This incomplete mechanistic
understanding likely stems from the use of over-simplified mathematical models, confounding factors
from data acquisition, and lack of sensitivity/specificity in the acquisition techniques to specific
biophysical processes. Regardless, numerous processes corresponding to known pathological processes
have been proposed for the observed changes in ADC values during and following treatment. As
Patterson et al. [18] summarize, events such as cellular swelling, reduction in blood flow, and tissue
compaction/fibrosis are proposed to result in lower ADC values, while processes such as apoptotic death
and necrosis might result in increased ADC values as the result of decreased cellular density. Strong
evidence exists to support increases in the ADC as an indicator of partial response to treatment [18],
[33]–[36]. Intuitively, these observations suggest cell death/necrosis resulting from successful treatment
will yield increased mobility of extracellular water (i.e., increased ADC). Cellular proliferation resulting
from progressing disease processes is thought to cause reductions in observed ADC values. Higano et al.
[37] observed a strong negative correlation between ADC and cellular proliferation, confirming that
hypothesis in patients with glioblastomas and astrocytomas. Researchers have utilized this rationale and
observed decreased ADC values [33], [37]–[39] in patients with progressive disease, and although some
groups observed no change in the ADC values with disease progression [40], [41] this discrepancy is
likely the result of small patient cohorts in these initial studies.
Although the ADC has been extensively investigated in numerous tissues, under certain
circumstances (e.g., in muscle or myelinated nerve fibers) diffusion becomes preferentially restricted in
one direction, resulting in diffusion anisotropy and necessitating additional measures to provide a more
complete description of water diffusion. Quantities such as the fractional anisotropy (FA) are often used
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to summarize the strength of ADC’s dependence on direction, with values falling in the interval between
0 (representing purely isotropic diffusion) and 1 (representing highly anisotropic diffusion) [42].
Quantification of anisotropy is performed using diffusion tensor imaging (DTI), which encodes this
additional directional information in the acquired images. The investigation of such quantities outside of
the central nervous system (CNS) is severely limited because most tissues lack the necessary
microstructural properties capable of generating anisotropic diffusion. However, in the CNS changes in
measured FA values might be indicative of the disease state. Comparison of histology and measured FA
values exhibited a negative correlation with cellularity in brain tumors [43]. Furthermore, investigations
of peritumoral FA values in brain tumors have revealed patterns of tumor infiltration [43]–[45].
Mechanistically, these observed differences in FA measures likely correspond to the increased cellular
disorganization and/or extracellular water content of tumors [45]–[47].
Despite the lack of general consensus regarding the mechanisms of ADC and FA change,
substantial evidence exists that suggests these QIBs are potentially important markers of treatment
response or proliferative disease when observed longitudinally during the course of therapeutic
intervention [18], [33]–[39]. ADC quantitation has been shown to track with changes in cellular density
and cellular proliferation in tumors, and associated changes in the ADC can be indicative of response
and proliferative disease. Moreover, some researchers have noted that diffusion QIBs provide early
indications of response [33]–[39], which could afford the opportunity to adapt treatments to nonresponsive disease. These current findings suggest that quantitative diffusion imaging is a promising
technique capable of assessing therapeutic response, even in shorter time frames than traditional
measures of response.

1.2.1

Perfusion and Vascular Permeability

Perfusion is the biophysical process by which blood is delivered to tissue via the capillary bed,
and is often summarized by a number of QIBs such as the relative cerebral blood flow (rCBF), relative
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cerebral blood volume (rCBV), and Ktrans, a rate constant describing an amalgamation of vascular
permeability and blood flow. These biophysical properties are investigated most commonly through the
use of low molecular weight extracellular exogenous contrast agents (CA). An intravenous bolus
injection and subsequent rapid imaging of the CA provides a means of assessing the distribution of the
contrast agent within the vasculature and, following extravasation, extracellular extravascular space
(EES). Pharmacokinetic models applied to these bolus tracking techniques provide a means of deriving
the aforementioned QIBs in addition to estimates of the relative EES ve. T2*-weighted imaging methods
are most commonly used to derive rCBF and rCBV (or more generally rBF and rBV in extracranial
applications) and are referred to as dynamic susceptibility contrast MRI or DSC-MRI techniques, whereas
Ktrans and ve are derived from T1-weighted methods collectively called dynamic contrast-enhanced (DCE)
MRI. As with diffusion imaging, the pathophysiology of cancer provides a unique opportunity for the
investigation of tumor perfusion and vascular permeability characteristics.
Nutrients are delivered to avascular tumors by passive diffusion, which limits the size of the
tumor to the approximate distance oxygen is capable of passively diffusing (1-2 millimeters). Further
viable growth is accomplished only through the recruitment of neovasculature (i.e., angiogenesis),
providing the necessary infrastructure to allow nutrients to reach the most interior regions of the tumor
to support the uninhibited growth of new cancerous cells [48]. Factors of the tumor microenvironment
such as pH, glucose concentration, and even certain oncogenes (e.g., p53) can result in the upregulation of vascular endothelial growth factor (VEGF), which, as the name suggests, promotes the
growth of endothelial cells eventually culminating in a neovascular network [10]. Histologically, this
neovascularization has been shown to correlate with increased microvascular density (MVD), which has
been shown to be an important biomarker of tumor stage and prognosis [49], [50]. In addition to rapid
growth of new blood vessels, vasculature recruited in this manner tends to be highly heterogeneous and
often contains numerous morphological defects, such as coarse capillaries with irregularly shaped
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vessels and tortuous paths [51]–[53]. These gross malformations, as Jackson et al. summarized [10], can
result in increased spacing between inter-endothelial junctions and a basement membrane that is
discontinuous or altogether absent, resulting in vascular hyperpermeabiltiy [54].
Both DCE- and DSC-MRI have shown promise in assessing these microvascular properties. In well
perfused tumors, histological measurements of MVD have been found to correlate with Ktrans in a
number of extracranial lesion types [55]–[57], although similar results in brain tumors remain
unestablished [58], [59]. However, Tynninen et al. [60] studied human gliomas and found a positive
correlation between MRI enhancement and cellular proliferation/MVD, but quantitative biomarkers
were uninvestigated. Since investigation of these parameters requires the extravasation of contrast
agent into the EES, varying levels of blood brain barrier (BBB) disruption in pathological processes,
especially in tumor boarders, of the CNS may result in a general lack of concordance between T1weighted quantities and histological markers. However, infiltration of brain tumor cells and vasogenic
edema can cause disruptions in the BBB, allowing passage of contrast agents into the extravascular
extracellular space [61]. The reduced permeability caused by an intact or partially disrupted BBB
provides an ideal scenario for DSC imaging. Specifically, several authors, using T2*-weighted imaging,
have shown correlations between MVD and rCBV in brain tumors [32], [56], [62]–[64].
These techniques have been employed in a number of studies to assesses response to radiation
and/or chemotherapy treatments in cancers of the bladder [65], breast [66], [67], cervix [57], [68],
rectum [69], and brain [70], where, similar to changes in the ADC, reductions in vascular permeability
(Ktrans) and relative blood volume generally corresponding to responding disease and increase tend to be
associated with disease progression. Despite these promising results, the assessment of antiangiogenic
agents is of substantially more interest in the application of QIB describing perfusion and vascular
permeability. Jackson et al. [71] and O’Connor et al. [72] have provided excellent reviews cataloging the
most up-to-date efforts employing perfusion/permeability imaging to assess these novel antivascular
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drugs. Initial results from a number of studies have shown Ktrans to be a predictor of both partial
response and progression. However, substantial heterogeneity exists in the results, and is likely the
result of small patient cohorts and a large variety in the treatment regimens and tumors sites.

1.2.2

Challenges

Standardization of data acquisition and analysis strategies is, perhaps, the most detrimental
factor preventing the widespread incorporation of quantitative imaging techniques into the clinical
setting [9], [19].This lack of standardization has resulted in a number issues, making the comparison of
published results difficult, preventing large multi-center trials, and slowing the validation of the many
proposed QIBS. In fact, much of the variation in the cited results of the previous sections can likely be
attributed to a combination of the lack of standard acquisitions/analyses and small patient cohorts.
Recent consensus documents have been published in an effort to address, specifically, the use of DCEMRI [73] and DW-MRI [19], and more generally, quantitative imaging recommendations [74]–[77].
Another common theme among these reports is the necessity for the development and
implementation of quality assurance methods capable of assessing sources of bias and variance in the
QIB acquisition and analysis pipelines [74]–[77]. As Leach et al. summarized [73], a number of
international committees have been formed, such as the ad hoc committee on standards for
quantitative MRI within the International Society for Magnetic Resonance in Medicine (ISMRM) and the
perfusion, diffusion, and flow subcommittee of the Quantitative Imaging Biomarker Alliance (QIBA).
Efforts by the perfusion, diffusion, and flow subcommittee have manifested in the development [78]
and ongoing accrual of multi-center data to assess equipment related bias and variance of DCE-MRI in
body applications, in addition to other independent efforts to quantify bias and variance in DWI and DTI
applications [79], [80]. These efforts are important not only for assessing bias and variance, but also for
the detection, evaluation, and mitigation of changes in scanner performance as the result of equipment
failure or software/hardware upgrades.
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As the development and implementation of standardized methodology and quality assurance
programs continues, incorporation of these techniques into clinical trials will expand, particularly those
encompassing multiple QIB acquisitions. Moreover, standardization will also facilitate the development
of robust software tools for quantitative imaging analysis, another set of tools requiring thorough
validation and characterization. Thorough understanding of the equipment and analysis related bias and
variance will provide a means of determining detectable limits of change in, and ultimately, in
conjunction with large patient cohorts, validation of quantitative imaging biomarkers.

1.2.3

Mapping Response using Multiple QIBs

Treatment-induced changes in normal tissue and tumors result in a multi-faceted, temporally
varying, spatially heterogeneous, biological response, especially in highly conformal and combination
therapies. Overwhelming motivation for the employment of quantitative imaging techniques for
assessing treatment response has been discussed in the preceding sections. Even a handful of studies
have simultaneously investigated multiple MRI QIBs to differentiate benign and malignant tumors [81],
assess treatment response [82], and develop mathematical tumor models [83]. Extracting useful
quantitative information from these techniques requires special consideration, and, moreover, instilling
utility into such extracted QIBs remains an immense challenge.
Research performed in much of the literature discussed previously is based on summary
statistics calculated over some region or volume of interest. Potential for incorporating multiple tissues
or missing nuance in tissue changes using this method is substantial. Appreciation for the spatial
heterogeneity of disease related changes has led many researchers to consider voxel-by-voxel analysis
methods such as histogram analyses [7], [82], [84], [85]. Although quantitative by nature, histogram
analyses destroy important spatial information contained in QIB parameter maps. Detecting spatial
heterogeneous information using such maps can be highly advantageous, but quantifying such
heterogeneity is extremely challenging. Perhaps the most important attempt at quantifying such
9

information to date is the development of the functional diffusion map [34] and, more recently, the
parametric response map [86]. These techniques utilize parameter map (ADC and rCBV, respectively)
differences, defining thresholds for positive and negative change from which voxel volume fractions are
calculated. By setting appropriate thresholds on the volume fractions of positive and negative change,
the functional diffusion map analysis provided a means of differentiating partial responders from those
patients with stable or progressive disease [34]. Similar findings were reported for the parametric
response map [86]. Although these analyses represented significant contributions to the detection of
disease states using parametric maps, spatial information relating QIBs directly to response was still
disregarded. As increasingly complex therapies are performed, establishing local relationships between
tissue QIBs and treatment response provides incredible promise to elucidate treatment associated
changes, potentially guiding clinical decisions, especially if multiple complimentary quantitative imaging
biomarkers are incorporated into such an analysis. To date, no reports of techniques capable of
assessing locoregional response in this way have been published.

1.3 Hypothesis and Specific Aims
Quantitative imaging biomarkers have shown promise in assessing response to a variety of
treatments in a number of anatomic sites. However, incorporating the complimentary information
contained in the QIBs of diffusion, perfusion, and vascular permeability into locoregional assessment of
treatment response remains as of unexplored. The objective of this research is to develop a
comprehensive and self-contained methodology for incorporating multi-parametric quantitative imaging
biomarkers into a statistical model capable of predicting locoregional radiological response. We
hypothesize that the incorporation of multiple quantitative imaging biomarkers into ordinal
regression models will better predict locoregional radiological response in post-surgical glioblastoma
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patients treated with intensity-modulated radiation therapy and temozolomide with or without
bevacizumab compared with the response predicted by a single quantitative imaging biomarker.
Specific Aim 1: Assess MRI equipment bias and variance. Phantoms will be developed to assess
equipment variance related to quantitative acquisitions, specifically dynamic contrast-enhanced and
diffusion-weighted (and diffusion tensor) imaging techniques. Weekly data acquisitions will be
performed to investigate longitudinal equipment level bias and variance. Additionally, these measured
variance levels will be used to simulate associated variances pharmacokinetic models that are not able
to be assessed through direct measurement of phantom properties.
Specific Aim 2: Implement and characterize software for assessing treatment response.
Comprehensive software tools for integrating quantitative modeling, image registration, and statistical
analyses will be developed. All quantitative models will be characterized to assess the algorithm
performance using digital reference objects.
Specific Aim 3: Predict locoregional response in a cohort of glioblastoma patients. Using the
software tools developed in specific aim 2, locoregional response will be defined by an experienced
radiation oncologist and used to develop ordinal regression models incorporating individual QIBs and
combined QIBs. These single parameter and multi-parametric statistical models will be used to predict
locoregional response.
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Chapter 2 Background and Theory

2.1 Quantitative Imaging
2.1.1

Diffusion

Robert Brown first described, in 1828, the random motion of pollen particulates in suspension.
Later, Alfred Fick derived an expression, commonly known as Fick’s First Law of diffusion [87], relating
the molecular motion of a solvent to an existing concentration gradient, written succinctly as
⃗

⃗⃗ ,

2.1

where ⃗ is the particle flux, ⃗⃗ is the concentration gradient, and D is the diffusion coefficient. Albert
Einstein showed in 1905 using kinetic theory that the random molecular motion first described by
Brown (i.e., Brownian motion) was, in fact, a diffusive process dependent on temperature and molecular
mobility [88]. In that seminal paper, Einstein showed, using Fick’s second law (in one dimension),

2.2

,

that the general solution to equation 2.2 for an n particle system is,

(

)

⁄

√
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and that the diffusion coefficient can be expressed in terms of the mean square displacement <R2> and
observation time t, given by
〈

〉

,

From this zero mean Gaussian (equation 2.3), the famous Einstein result is easily extracted
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2.4

√〈

〉

√

,

2.5

yielding the simple interpretation that the root-mean-square displacement is proportional to the square
root of the time that has elapsed since the initial state of the system. In other words, the longer a
system of particles is allowed to undergo random molecular motion, the greater the root-mean-square
displacement of those particles. This result is easily extensible to three dimensions, noting that the
integral used to generate equation 2.5 becomes a volume integral over all space, resulting in
√〈

〉

√

.

2.6

Even in the absence of chemical gradients these general results still hold, in which case, D is referred to
as the self-diffusion coefficient. In the context of imaging measurements, D is generally the value of
interest and the term “apparent” is appended to draw a distinction between the measurement of selfdiffusion and the measurement of molecular motion in a complex biological system, yielding the term
apparent diffusion coefficient or ADC. Biological systems, as will be discussed later in this section, can
encompass numerous biophysical phenomena other than self-diffusion alone. Despite this distinction,
ADC and D are used interchangeably in the following discussions, especially when mathematical
expression can be simplified.
When considering the measurement of diffusion, especially in biological tissues, directional
dependence of diffusion may be encountered. Muscle and myelinated nerve fibers are examples of
biological structures in which water diffusion becomes directionally restricted or, in other words,
diffusion of molecules is oriented preferentially along the length of the fiber. In such cases, a single
proportionality constant describing the ability of particles to disperse as a function of time becomes
insufficient. For a homogenous medium, this process can be represented by a second-rank tensor, Dij for
i and j=x, y, z or
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(
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2.7

where Dij represents the ith component of diffusion along the jth axis. In practice, this can be interpreted
as the ith component of diffusion process measured through observations along the jth direction. Fick’s
second law can be extended to incorporate the directional dependence (i.e., the diffusion tensor). When
considering self-diffusion in the absence of other forces influencing the process (e.g., active transport),
the diffusion tensor becomes symmetric (i.e., Dij=Dji). This additional symmetry results in the diffusion
tensor being uniquely determined by six terms, the terms along the diagonal and either the three
elements above or below the diagonal. If the coordinate systems of the physical process and the
observations were perfectly aligned, the off-diagonal components of the diffusion tensor would be
identically zero, with the values along the diagonal known as the principle diffusion coefficients. In
practice, the orientation of the diffusion processes is unknown and the unique components of the
tensor must be observed. Diagonalization can then be performed to recover the principle diffusion
components, which are invariant regardless of the orientation of the measurement or laboratory
coordinate system. This reduces equation 2.7 to

(

)(

),

2.8

where the three principle diffusion components or eigenvalues λi’ represent the diffusion coefficient in
the new “prime” coordinate system specified by the basis of eigenvectors εi’ or diffusion directions,
where the result of equation 2.5 can be shown to hold for each of the three eigenvalues (i.e., √
i'=x’,y’,z’). Note that in an isotropic medium, this formalism reduces to that considered by Einstein,
where the scalar
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{

2.9

which is equivalent to the initial formulation by Einstein. Tensor formalism gives a complete description
of the physical system, but generates an enormous amount of data, three eigenvalues and eigenvectors
to be exact, although knowledge of certain systems might suggest that there are only two unique
eigenvalues and eigenvectors. Especially when these values are computed on a voxel-by-voxel basis,
rotationally invariant summary parameters (i.e., those that depend only on the underlying physical
process, not the frame of observation) become increasingly important. Two of the most commonly
employed parameters are the mean diffusivity (MD)
(

)

2.10

and fractional anisotropy (FA)

√

(

√∑

)

2.11

∑

both of which have been investigated frequently as QIBs [18], [19] . The latter, FA, was proposed by
Basser and Pierpaoli [42], and achieves values ranging from 0, which represents a purely isotropic
medium (equation 2.9), to 1, indicative of a cylindrical anisotropic medium (i.e., λx’>> λy’= λz’, or any
other permutation of the directional indices).
Stejskal and Tanner [89] were the first researchers to describe a method for sensitizing the MRI
signal to the diffusion properties of the object or patient being imaged. The proposed pulse sequence
incorporated two rectangular pulsed gradient fields (PGF) of equal magnitude G and duration δ
separated by a time interval of Δ, and followed by a standard spin-echo (SE) imaging sequence. During
the interval Δ, a 180o RF pulse is applied, which, in combination with the second gradient pulse, causes a
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reversal of the phase accumulated during the first gradient pulse. Stationary spins experience the same
local magnetic susceptibilities throughout this pulse sequence and the resulting signal intensity is
unaffected. However, diffusing spins will experience changing magnetic susceptibilities while traversing
the molecular environment, resulting in a net signal loss following this pulse sequence. More specifically,
solving the Bloch-Torrey equation [90] for the PGF sequence gives
(⃗

(

)

)⃗ ⃗

,

2.12

where γ is the gyromagnetic ratio, ⃗ is the applied gradient vector, S0 is the thermal equilibrium signal
intensity1, TE is the echo time, and R2* is the transverse relaxation rate; all other parameters are as
defined previously. The direct product or dyadic of the magnetic gradient vector is defined as

⃗ ⃗
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)

2.13

where αx, αy, and αz are the directional cosines of the applied diffusion encoding gradient. In most
applications, a single user-adjustable imaging parameter b (or the b-value) is used in lieu of the
timing/amplitude values, and is defined as
(⃗

(

)

) ⃗ ⃗,

2.14

which allows recasting of equation 2.12 into the canonical form
(

)

.

1

2.15

S0, more specifically, is a combination of the proton density, receiver gains, and, potentially, image reconstruction
techniques.
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Although this development has assumed an ideally rectangular pulsed gradient, analytical expressions
can be derived for many other physically realizable gradient waveforms [91], including effects of the
imaging gradients on the b-values [92].
The theoretical developments by Stejskal and Tanner made no assumptions regarding the
underlying microstructural tissue properties or other physiological properties affecting DW signal
intensities. Le Bihan et al. [93] posited that compartmentalization of water in perfused capillaries can
generate diffusion-like (or pseudodiffusion) reductions in signal intensity that actually result from
perfusion effects. A subsequent publication [94]by that same group resulted in the development of a
model to describe pseudodiffusion, yielding
(

)

)

[(

]

2.16

where D* is the pseudodiffusion coefficient describing water movement in capillaries that appears as a
diffusion process (i.e. exponentially decaying), f is the perfusion fraction, and all other symbols are as
defined previously. Interestingly, accounting for the perfusion fraction (essentially the fractional volume
of plasma space) in this way allows comparisons with T1-weighted pharmacokinetic models that
explicitly account for fractional plasma volume, which recent results suggest agree well in prostate
cancer and the corresponding contralateral normal tissue [95]. Many other models describing, for
example, the non-Gaussian characteristics of restricted diffusion and compartmental models have been
proposed and investigated [96], but the models described by equations 2.15 and 2.16 are, by far, the
most commonly employed.
In vivo quantitation of diffusion, especially for the purposes of assessing treatment response, is
performed primarily under two paradigms, one for tissues in which isotropic diffusion is expected and
the other for the case of anisotropic diffusion. In this discussion of diffusion modeling the effects of
diffusion on the MRI signal, no assumptions regarding the diffusion isotropy have been made despite
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continued appearance of the diffusion tensor in equations 2.12 through 2.16. Rather, a more general
approach was taken, which results in greatly simplified models under circumstances when anisotropy
can be or is purposely neglected, and will be the focus of section 2.1.1.1.

2.1.1.1 Quantitative Diffusion – Acquisition Strategies
As described earlier in section 2.1.1, most biological tissues exhibit restricted isotropic
diffusion of water molecules and a single summary parameter, ADC, suffices to describe the system.
Under these circumstances, the diffusion tensor reduces to a constant or zeroth-rank tensor, and by
ignoring the directional component of b reduces the previous linear algebra operators of equation 2.15
are reduced to the scalar products of b and D. By acquiring images using at least two unique b-values,
keeping the TE and timing parameters of b constant, regression analysis (linear or non-linear) can be
performed to derive the diffusion coefficient. Historically, two acquisitions were used to derive the ADC,
and consisted of one image without diffusion weighting (i.e., b≈0) and a second image with a non-zero
b-value. However, when modeling is performed with equation 2.15, mounting evidence, as reviewed in
a recent consensus report of DWI by Padhani and Liu [19], suggests that multiple b-values (i.e., more
than two) should be used and that both small and large b-values (<100 s/mm2 and >1000 s/mm2) should
be carefully considered in the design of acquisition protocols to avoid perfusion effects and the biexponential behavior exhibited by the DW signal at high b-values, respectively. More advanced
modeling, such as the IVIM model, necessitates the acquisition of more than two b-values to uniquely
determine the model parameters.
In addition to varying the b-values, acquisitions are commonly performed by utilizing the same
set of b-values acquired in multiple directions, most commonly in three mutually orthogonal directions
yielding ADCx, ADCy, and ADCz. A number of useful acquisition schemes have been proposed for the
acquisition of these three ADC values. Perhaps the simplest and most commonly used schema acquires
images with diffusion encoding parallel to the physical gradient axes (Gx, Gy, and Gz). So called
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tetrahedron encoding can provide improvements in signal-to-noise ratio (SNR) (recall the TE
dependence of equation 2.15) over this simple scheme. By combining pairs of gradients (Gx/Gy, Gx/Gz,
and Gy/Gz), which effectively increases the maximum gradient strength by a factor of 1.4 and reduces
the pulse duration Δ, the echo time can be reduced, resulting in less T2* dephasing and increased SNR.
For isotropic tissues, the resulting ADC values should be equal, disregarding differences in gradient
performance, but in tissues with anisotropic diffusion, these values are rotationally variant and can
depend on external factors such as patient orientation. Despite the lack of rotational invariance, DWI
acquisitions have found clinical utility in the neurological evaluation of strokes, infections, head trauma,
tumors, and hemorrhages [97]. Furthermore, multi-directional DWI acquisitions can provide a rapid
means of qualitatively assessing anisotropy (or confirming assumptions about isotropy).
Anisotropic tissues are described only partially by DWI quantification methods, requiring
computation of the diffusion tensor for a more adequate description. Recall that a minimum of six
elements are required to uniquely determine the diffusion tensor. By solving equation 2.15 for the
argument of the exponential term containing the tensor and absorbing the T2* decay term into S0, an
expression relating the b-values and diffusion tensor elements is given by
(

(
(

)
)
)

.

2.17

Expansion of the Frobenius inner product of the b-matrix and diffusion tensor gives rise to a six term
linear equation for each applied direction of the diffusion gradient, assuming that Dij=Dji. If six non-zero,
non-collinear, non-coplanar, b-values are acquired, in addition to an image without diffusion weighting,
equation 2.17 represents a linear system of six equations that uniquely determine all elements of D.
Therefore, a minimum of six diffusion weighted images and one non-diffusion weighted image, for a
total of seven images, are required to determine the diffusion tensor. Basser et al. [98] first described a
method of multiple linear regression for determining the elements of D when using this minimal
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acquisition strategy. As the number of diffusion weighted images (N) increases beyond six, the method
of singular value decomposition is usually employed to find a solution to the N linear equations of2.17.
Acquisitions on commercially available clinical systems usually present the user with a choice only for
the number of diffusion directions to acquire and a pre-computed set of gradient strengths and
directions are used to perform serial imaging.
Diffusion tensor imaging is wrought with trade-offs. In clinical settings, limited scanner time and
issues such as patient motion (DTI and DWI are, after all, serial image acquisitions) place constraints on
the number of quality images that are able to be acquired. Two primary acquisition parameters
determine the image quality and acquisition time: the number of diffusion encoding directions and the
number of signal averages to perform on each acquired image. A theoretical study of noise by Bastin et
al. [99] showed that, below an SNR value of 20, components of the diffusion tensor rapidly diverged
from ground truth. SNR can be controlled in the acquisition by averaging the signal, essentially acquiring
the same data multiple times and averaging, or by increasing the number of diffusion encoding
directions. For diffusion gradient schemes acquiring the absolute minimum number (or near that) of
directions, signal averaging must be used to improve image SNR, especially as the magnitude of the bvalue increases. However, as the number of acquired encoding directions increases, the amount of time
required to perform signal averaging becomes too expensive, but the acquisition of these additional
images with, diffusion encoded in different directions, also improves image SNR. Additionally, Armitage
and Bastin [100] and Jones et al. [101] have shown that too few encoding directions unnecessarily biases
tensor estimates, while Poonawalla and Zhou [102] showed that the SNR improvements fall of
drastically after the number of encoding directions exceeds approximately 25.

2.1.2

T1 Relaxometry

Quantitation of longitudinal relaxation rates, R1 (usually quoted in units of s-1), generally requires
modeling of the signal intensity, averaged over an ROI or taken from an individual voxel, as a function of
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one variable acquisition parameter. Two common techniques are based on the extension of common
imaging techniques (e.g., FSPGR and IR-SE) to include multiple imaging parameter settings such as
variable flip angles (VFA) and variable inversion times (VTI). Numerous other techniques, such as the
Look-Locker sequence, saturation recovery, and stimulated echo acquisitions [103], have been
developed and employed frequently for research purposes. However, these newer techniques remain
unavailable on commercially-available clinical equipment, and since the goal of this work was to address
quantitative imaging in a clinical setting, the following discussions are limited to those acquisition
strategies currently available on clinical systems.
Spoiled gradient echo sequences provide a time efficient method of estimating relaxation rates
for 2- or 3-D image sets. This is accomplished by acquiring images using two or more unique RF
excitation flip angles, hence the name variable flip angle, while keeping all other acquisition parameters
constant. By solving the Bloch equations, assuming that steady state has been reached and that perfect
RF spoiling is occurring, the signal intensity as a function of the RF excitation angle (α) can be written as

(

)

( )

( )

2.18

where S0 is the thermal equilibrium signal intensity, TR is the repetition time, TE is the echo time, R1
(=1/T1) is the longitudinal relaxation rate, and R2* is the transverse relaxation rate. Equation 2.18 can be
simplified by noting that TE is generally held constant as a function of flip angle in these types of
acquisitions, and, moreover, that the scan parameter TE can, in many cases, be assumed to satisfy the
relation T2*(=1/R2*)<<TE, yielding the product TE∙R2* is approximately zero and an exponential term of
nearly unity. This results in the following simplified expression for the MRI signal intensity:

(

)

( )

21

( )

2.19

In certain instances, particularly when the specific absorption rate (SAR) limit is being approached,
manufacturers will change the RF pulse structure causing slight changes in TE, but this assumption still
holds to a first approximation, and these limits are rarely reached in brain applications. Generally
speaking, all parameters (except for TR) of equation 2.19 are functions of spatial position. Although the
acquisition and processing of serial images implicitly accounts for the spatial distribution of signal and
relaxation rates, a more stringent assumption is often placed on the flip angle, namely that of spatial
invariance. Therefore, any deviations in the flip angle, which can arise from transmit miscalibrations or
spatial heterogeneity of the B1 field, can and are known to cause errors in R1 estimates [104].
Inversion recovery based relaxometry methods offer enhanced robustness with respect to
systematic errors that plague other strategies (e.g., RF heterogeneity of VFA acquisitions), and superb
signal-to-noise ratio (SNR) efficiency [103]. Specifically, a spin-echo inversion sequence consists of a
single 180° RF pulse followed by a programmable delay and a standard spin-echo imaging sequence.
Solving the Bloch equations for arbitrary inversion times, inversion flip angle, and relaxation rates
provides the following result,
(

)
(

(

)

(

)

2.20
)

where TI is the inversion time, θ is the inversion pulse flip angle, and all other quantities are as defined
previously. Assuming that TE<<T2, a reasonable assumption for most acquisitions, the R2 dependency is
removed, as discussed for the FSPGR acquisition, resulting in
(

)

(

(

)

(

)

)

Further simplifications can be made if the echo time is assumed to be much less than TR, which is
generally the case in T1 relaxometry techniques since TR is frequently chosen specifically to satisfy
TR>5∙T1, which allows full or nearly full recovery of the longitudinal magnetization to thermal
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2.21

equilibrium. In combination, these assumptions provide the following simplified form of the Bloch
equations solution:
(

)

(

(

)

)
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Rarely in practice is the nominal inversion flip angle of exactly 180° achieved, which is corrected here by
the model parameter, θ. To appropriately satisfy all of the simplifying assumptions of this model,
imaging times for this sequences can become prohibitively long (e.g., a single slice, 256x128 matrix
requires a 10 minute acquisition with TR=5s), requiring more temporarily efficient imaging sequences
such as fast spin-echoes, which can introduce additional errors in parameter estimation. When
processing VTI data, another potential concern arises from the fact that images are generally computed
and stored as magnitude data; the acquired complex raw data are not stored. Computation of the
magnitude images changes the structure of noise in the image from a zero mean Gaussian distribution
to a Rician distribution [105], particularly in the low SNR regions surrounding the null point –
TInull(=ln(2)/R1) [12]. This can create bias in the parameter fits, which is mitigated by using the raw
images or, to a lesser extent, by inverting the signal intensity of voxels in the magnitude images
satisfying the condition TI<TInull.

2.1.3

Dynamic-Contrast Enhanced-MRI

DCE-MRI refers to a collection of MR imaging techniques that utilize exogenous contrast agents,
most frequently injected intravenously, to increase (i.e., enhance) the observed MRI signal intensity.
Gadolinium(III)-based, or Gd for short, contrast agents exhibit favorable properties for preferentially
increasing longitudinal relaxation rates, i.e., relatively large T1 relaxivity, while minimally disrupting
magnetic susceptibility, i.e., relative small T2 relaxivity, and, although these properties are not unique to
Gd (e.g., manganese exhibits similar paramagnetic properties), FDA and other regulatory organization
approval and wide clinical availability of the low molecular weight (<1 kDa), extracellular agents, such as
23

gadopentetate dimeglumine (Gd-DTPA) delivered intravenously have provided the scaffold for
innumerable quantitative clinical studies [106], [107]. Within several seconds following contrast agent
(CA) injection, these agents pass through the vasculature and begin to distribute in the extracellular
extravascular space (EES) of tissues exhibiting vascular permeability to such agents, which include most
extracranial tissues and regions of the CNS with blood brain barrier (BBB) disruptions. This distribution
of CA within the vascular system and, subsequently, in the EES of tissues forms the basis for the
application of pharmacokinetic models. Although other approaches to quantification exist, such as CA
time course shape analysis and semi-quantitative (or model-free) descriptors of tracer kinetics, the
following development focuses on pharmacokinetic (PK) models with physiologically meaningful
parameters [10].

2.1.3.1 Tracer Pharmacokinetic Models
Kety first described the kinetics of a freely diffusible tracer in which the rate of equilibration
between the arterial and extravascular tracer concentrations was modeled [108]. In this early model,
two compartments were considered: a vascular compartment and a tissue compartment. If a diffusible
contrast agent is well-mixed and distributed uniformly in these two compartments with direct access to
the water population, then a simple rate equation can describe the system. Tofts and Kermode [109]
showed that the model developed by Kety [108] could be recast in terms of an extracellular CA
concentration in the EES, Ce(t), fractional volume of the EES, ve, and the CA concentration in the plasma
space, Cp(t), giving
( )

(

( )

( )),

2.23

where Ktrans is the initial CA transfer rate from the plasma to the EES using the proposed consensus
notation of Tofts et al. [110]. This model and these parameters are represented schematically in Figure
2-1. The quantity Cp(t) is known as the arterial input function, or more generally as the vascular input
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function (VIF), and Ce(t) represents the CA concentration. Calculation of an integration factor turns this
simple ordinary differential equation (2.23) into a separable differential equation, the solution of which
is

( )

(

( )

∫

)
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or more compactly
( )
where

( )

( ),

2.25

is the convolution operator and H(t) is the impulse response function given by

( )

.

2.26

Using this formulation, equation 2.25, in conjunction with 2.26, can be described intuitively as follows:
extravasation of plasma tracer into the EES proceeds initially at a rate given by Ktrans and results in the
immediate exponential decay of EES tracer concentration at a rate of kep (≡Ktrans/ve).
In quantitative imaging studies, Ce(t) is measured from either a voxel or region of interest, which
is relatively large when compared with the size of the EES and/or plasma space. If contributions from the
latter can be ignored, then the tissue concentration is given by
( )

( ).
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In normal brain, even when EES concentrations are estimated over relatively large volumes that might
include plasma contributions, this relationship holds to a first order approximation as the vascular
volume is on the order of 2-4% [109]. However, in highly vascular pathologies, such as glioblastomas,
non-negligible vascular contributions may unduly bias the estimated tissue concentrations, resulting in
overestimates of Ktrans (known as pseudopermeability) [111]. A simple model accounting for the
additional plasma volume is given by assuming tissue concentrations of the form
( )

( )

( ),

2.28

where vp is the fractional plasma volume, and noting that, in general, vp+ve≠1. Substitution of equation

Figure 2-1. Two compartment kinetic model schematic. The pharmacokinetic model most frequently
used in the analysis of DCE-MRI data consists of two compartments separated by the endothelium:
an extracellular extravascular space (left) and a vascular space (right). Ktrans describes the transfer
rate constant of contrast agent from the vascular to EES space, ve describes the fractional EES
volume, and vp describes the fractional plasma volume. The parameter kep is defined as Ktrans/ve.
Arrows indicate blood flow through the vascular space.
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2.28 into 2.25 yields the so called modified Tofts-Kermode or generalized kinetic model (GKM) [110],
given by
( )

( )

( )

( ).
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At this point, the model parameters describing the fractional intravascular and EES volumes
have been described, but Ktrans remains a simple initial rate constant without any other physical
interpretation. Returning to equation 2.23 and considering the initial state of the system provides a
means of interpreting Ktrans. Prior to and during the initial arrival of contrast in the tissue, the rate of
change in the EES CA concentration will be proportional to the blood flow. Moreover, for some time
following the injection of CA, the EES CA concentration is negligible and, and equation 2.23 can be
written as
( )

(

)

( ),
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where F is the flow of whole blood per gram of tissue, ρ is the tissue density, and the parenthetical term
accounts for the fact that the CA in this discussion is extracellular agents. Equating the right hand sides
of equations 2.23 and 2.30, after some algebraic manipulation, gives the following results,

(

)

(

( )

( ))
( )

(

)

,
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where the fraction of tracer concentration initially extracted into the EES is known as the extraction
fraction E [110]. Renkin, in a study of postassium-42 tracer, modeled capillaries as a permeable cylinder
with permeability P and surface area S [112], and Tofts et al. [110] reformulated this result using the
proposed standard notation, giving

27

(

( )

( ))

⁄ (
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The general form of Ktrans can thus be written as

(

⁄ (

) (

) ),

2.33

where Ktrans is a combination of the permeability surface area PS and capillary flow. Two mathematically
limiting cases of this model are often discussed: flow limited (F<<PS) and permeability limited (PS<<F)
[10], [12], [110]. The former results in the original model proposed by Kety [108] (i.e., Ktrans is
proportional to F) and the latter, with the help of a Taylor expansion, yields

(

) (

(

(

)
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While these limiting cases provide simple interpretations of Ktrans, in general, the underlying physiology
frequently renders both limiting cases unreasonable approximations and Ktrans must be interpreted as an
extraction-flow product dependent upon capillary flow and permeability surface area.
Not surprisingly, a plethora of other pharmacokinetic models have been proposed. Li and
Jackson [113] proposed a simplified method for extracting GKM parameters from only the first pass of
tracer. St. Lawrence and Lee [114] proposed the adiabatic approximation to tissue homogeneity model,
which exploits the early flow-limited (i.e., Ktrans is proportional to F) phases of contrast enhancement
followed by a general mixture of flow and permeability (equation 2.33) to allow the computation of
blood flow. Models of increasing complexity introduce additional challenges to acquisition and analysis
strategies, which will be discussed in detail in the following sections, and have slowed the wide-spread
adoption of more sophisticated models, leaving the GKM the most widely employed pharmacokinetic
model in the analysis of low molecular weight Gd-based CA.
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2.1.3.2 Quantitative DCE-MRI – Acquisition and Analysis Strategies
Gadolinium based CAs, as discussed at the beginning of section 2.1.3, can be used to affect
the longitudinal relaxation rates of biological systems, and in conjunction with a T1-weighted imaging
strategy and PK model allow investigation of vascular permeability/flow effects. More specifically, the
interaction of protons with this paramagnetic complex result in an increase in the native longitudinal
relaxation rate R10, which can be described by a simple linear relationship
,

2.35

where R1 is the resulting longitudinal relaxation rate of the sample, r1 is the T1 relaxivity of the Gd-based
CA in units of mM-1s-1, and [Gd] is the concentration of the CA in mM. Dipole-dipole interactions (the
dominant source of longitudinal relaxation mechanisms in liquids and soft tissues) are inherently short
range, requiring direct access to a water population, and therefore require a substantive distribution of
Gd throughout the observed compartment to affect changes in the MRI signal. Quantitative DCE-MRI
modeling utilizes imaging protocols that minimize the effect of this R20 shortening (namely, short TE
acquisitions) and exploit the changes in R10, manifested as changes in MRI signal intensity, to indirectly
observe the distribution of Gd throughout the intravascular and EES compartments by rapidly acquiring
T1-weighted images prior to and following injection of the CA.
T1-weighted FSPGR sequences (discussed in some additional detail in section 2.1.2) have been
used extensively for DCE-MRI acquisitions as these techniques are capable of acquiring relatively large
volumes with reasonable spatial (sub-millimeter in plane) and temporal (~5s) resolution, allowing
coverage of the anatomy being investigated while providing adequate temporal estimation of CA
concentration used in the PK model. Prior to CA injection, a cinematic sequence of acquisitions is
initialized capturing the pre-contrast signal intensities. After a number of pre-contrast frames have been
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acquired, the CA is injected intravenously followed by several more minutes of image acquisition. Before
PK modeling can occur, the signal intensity must ideally be converted into [Gd].
Assuming that the [Gd] remains low enough such that T2*<<TE and that the presence of CA has
an inconsequential impact on the proton density (i.e., S0 is constant), then the signal intensity as a
function of time is given by combining equations 2.19 and 2.35

(
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)
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(
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(

,
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where α is the flip angle. For convenience, define the constant quantity

2.37

( )

and consider the ratio of pre-contrast signal intensities, say Spre, to the post-contrast time-varying signal
intensity of equation 2.36. Through careful algebraic manipulation, [Gd] as a function of observed preand post-contrast signal intensities can be shown to be
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)

(
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At this point, the relationship between [Gd] and MRI signal intensity can be seen to depend only on the
known acquisition parameters α and TR, the Gd relaxivity r1, and the native longitudinal relaxation rate
R10. Generally, a single value is assumed for the relaxivity, which will depend on temperature, magnetic
field strength, and the physiochemical environment (e.g., tissue type) [115], [116]. However, there are
principally two approaches to providing a value for R10. In one approach, R10 is estimated using, for
example, the FSPGR method of section 2.1.2. The resultant relaxation rate maps can then be used in
conjunction with the dynamic series images to calculate [Gd] on a voxel-by-voxel basis, but additional
uncertainties in the estimation of R10 will propagate through to the calculation of [Gd] and ultimately to
the PK parameters. Another common approach is to assume that R10 varies minimally across various
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tissues and pathologies (see, for example, the reviews of Bottomley et al. [117], [118]) and assume a
single relaxation rate for tissue (usually 1000ms) and one for the intravascular compartment (usually
1440ms). Haacke et al. [85] showed that assuming a constant value for the intrinsic longitudinal
relaxation rate resulted in more reproducible results. Although biases may be present, there is a paucity
of evidence suggesting that these biases would necessarily vary significantly over relatively short
durations of chemotherapeutic or radiation therapies and would, there, have little impact on PK
parameters changes [119].
A second, more parameter independent, approach is also used commonly in literature. Again,
assuming that S0 and T20* are unaffected by the presence of [Gd], and that the TR<<1/R1, a Taylor series
expansion of the exponential terms in equation 2.36 results in
(
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Furthermore, in the limit as the flip angle α approaches 90o this expression reduces to
(

( )

)

.

2.40

Applying these same approximations to the pre-contrast signal intensity and taking the difference in
post- and pre-contrast signal intensities yields a simple result,
,

2.41

Therefore, for large flip angles, the change in signal intensity following administration of the CA is
proportional to the [Gd] within a constant scaling factor (S0∙TR∙r1). However, as the [Gd] increases, the
assumption that TR<<1/R1 rapidly degrades the validity of this approximation, and the resulting
concentrations are underestimated. Regardless, these approximations provide a method of quantifying
PK parameters without a priori knowledge of the inherent relaxation rates.
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The last crucial component in the quantitative analysis of DCE-MRI data is the selection of an
appropriate VIF. Early researchers, Tofts and Kermode [109], Weinmann et al. [120], and Brix et al.
[121], for example, used empirically derived population averaged models to describe the VIF. However,
the VIF time course is intimately dependent on exam specific factors such as CA injection rate and dose,
and, more importantly, on patient specific factors such cardiac output, pharmacokinetic distribution of
the CA, and kidney glomerular filtration rates, all of which can exhibit considerable variance. As
hardware performance has improved, fast imaging techniques capable of capturing the rapid changes in
signal intensity resulting from a CA bolus have become commonplace. Although some disagreement
regarding the reproducibility of the respective methods exists [122], [123], measurement of individual
patient VIFs is generally accepted to be more physiologically accurate [10], [12].

2.1.3.3 Quantitative DCE-MRI – Additional Considerations
Throughout the preceding discussions of DCE-MRI modeling, the distribution of CA in the
intravascular and tissue compartments was described appropriately as a continuous physical process.
However, in practice, the image sampling rate is limited as a result of hardware limitations and
application specific acquisition parameter choices. To date, several researchers have investigated the
effects of temporal resolution on PK estimates. Early investigations by Karmonik and Jackson [124]
found a temporal resolution of less than 4s was required to ensure that the 95% confidence interval of
Ktrans estimates was within 10% of the true value. Henderson et al. [125] later corroborated these
findings, showing that sampling intervals of once every 4s are required to ensure that Ktrans and ve are
within 10% of the true values. For the adiabatic approximation to tissue homogeneity model, Kershaw
and Cheng [126] showed unavoidable bias and variance were introduced unless images were sampled at
least once every 3s. Notably, these sampling rates allow adequate measurement of the rapid VIF
kinetics, with tissue kinetics requiring substantially lower temporal resolution [125]. To circumvent these
stringent temporal resolution requirements, Kovar et al. [127] proposed a reference region that utilizes
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a nearby enhancing region, such as muscle, in lieu of measuring a VIF, a method that was further refined
by Yankeelov et al. [128]. Heisen et al. [129], using such tissue reference methods, showed significant
reduction in the temporal resolution requirements, i.e., data acquisition only once every 20s, still
provided accurate quantification. However, in brain applications, the lack of enhancing structures in the
imaging volume is problematic for reference region models. Moreover, in applications assessing
treatment response, identification of a suitable region that remains unaffected by the treatment
regimen becomes increasingly problematic.
Aside from the strict temporal requirements of DCE-MRI, the discussions of section 2.1.3.2
assumed that the tissue and intravascular compartments contained a homogenous water population
that interacted directly with the Gd complex. In biological tissues, water is further compartmentalized
within tissues, with a majority contained inside the constituent cells. Inter-compartmental transit of
these water molecules can render the simple linearity described by equation 2.35 invalid. If little
difference exists between the relaxation rates of the compartments, then the observed compartments
will exhibit a nearly single valued relaxation rate (an average of the compartments’ rates) and the linear
relationship between [Gd] and R1 holds. Under these circumstances , the compartments are said to be in
the fast exchange limit or fast exchange regime [115]. Conversely, the slow exchange regime results
from large differences in compartment relaxation rates. Donahue et al. [115] showed that both regimes
can be present in a given DCE-MRI study, with intravascular-EES compartments exhibiting slow exchange
and intracellular-EES compartments giving rise to fast exchange. Implications of the former effect were
studied by Larsson et al. [130], and concluded to have minimal impact on the quantification of PK
parameters, specifically Ktrans, at clinical doses, a result corroborated by Buckley [131]. Evidence strongly
suggests that the fast exchange limit reasonably approximates intracellular-EES water exchange for
clinically relevant doses, usually 0.1 mmol/kg [115], [132]. Despite this evidence, researchers such as
Landis et al. [133] and Yankeelov et al. [134] argued that this linearity holds for only a limited range of
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tissue concentrations, which prompted the investigation of transcytolemmal water exchange and the
development of the “shutter-speed” model to addresses the effect of compartmental water exchange
rates. However, Buckley et al. [135] showed that the clinically relevant acquisitions were insensitive to
this exchange, warranting the use of simpler models that assume the fast exchange limit, especially
when coupled with short TR values and large flip angle FSPGR acquisitions [136].
Other notable sources of bias and, potentially, variance exist in the analysis of DCE-MRI data,
such as differences in artery and capillary hematocrits, choice of the VIF, spatial R10 estimation, and
environment dependent r1 values. For these factors, some remain uninvestigated in the literature, and,
for others, consensus regarding appropriate analysis methods has yet to be reached. By maintaining
consistency in the choice of analysis and acquisition techniques, the model associated variances will be
minimized despite potential biases. Moreover, in the context of treatment assessment, reproducibly
biased methods reign supreme over those exhibiting lower bias and higher variance, as ultimately the
goal is to detect changes, not absolutely quantitate physiological parameters.

2.1.4

Dynamic-Susceptibility Contrast-MRI

In the scientific literature, the terms DCE and DSC are occasionally used interchangeably, but for
the following discussions DSC-MRI refers specifically to the collection of MR imaging techniques that
exploit the magnetic susceptibility of paramagnetic contrast agents, in a manner analogous to DCE-MRI,
to modify the observed MRI signal intensity. Unlike DCE, T2- or T2*-weighted sequences are used to
observe the associated changes in the bulk magnetic susceptibility, affecting a decrease in signal
intensities, rather than the enhancement seen in the T1-weighted counterparts. When these
extracellular contrast agents are confined to relatively small regions, such as the intravascular space, for
example, large local magnetic fields resulting from the paramagnetic properties of Gd induce increases
in the transverse relaxation rate. However, the compartmentalized CA is unable to directly interact with
the large extravascular water population, minimizing the associated T1 changes, and resulting in a
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disproportionately large change in R2 or R2*. Analogously to T1-weighted techniques, rapid T2- or T2*weighted imaging sequences provide a means of temporally estimating the CA distribution through the
vasculature, allowing quantitation of physiological parameters and, if desired, semi-quantitative
descriptors.

2.1.4.1 Tracer Pharmacokinetic Models
Early work by Meier and Zierler [137] culminated in the basic mathematical description used
most frequently to describe the pharmacokinetics of non-diffusible tracers. These methods were later
extended beyond initial applications utilizing injected dyes, ultimately providing a means of using
extracellular contrast agents to imaging modalities such as MRI [138] to quantify cerebral blood flow
and volume. While early researchers such as Østergaard et al. [138] and Sorensen et al. [139] quantified
blood flow in brain tumors, Aronen and Perkiö [140] noted that the use of blood flow in evaluating highgrade brain tumors (the subject of this work) may be less appropriate than the cerebral blood volume
owing to the poorly formed highly heterogeneous (spatially and temporally) vasculature. With this
consideration, the following discussions will focus primarily on the quantification of the relative cerebral
blood volume (rCBV).
Consider a closed vascular system (i.e., the CA remains intravascular) in which a CA is
delivered through a single inlet, subsequently exiting the system through a single outlet. If CA
recirculation is prevented, the amount of CA that passes through some volume of interest, C(t),
normalized by the total amount contrast injected into the system measured from a AIF, Ca(t), can be
represented as [10], [12]
∫

( )

∫

( )
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,

2.42

where Hf is the hematocrit factor, ρ is the tissue density, and t0 is the time at which the CA
concentration becomes different from zero. The hematocrit factor, Hf, accounts for the difference in the
hematocrits of small and large blood vessels, and is given by
(

)⁄(

).
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Clearly, in clinical practice, preventing CA recirculation is impossible, resulting in concentration time
curve that include contributions from the first-pass kinetics and subsequent CA recirculation. An
example [Gd] recirculation as seen in a VIF is given in Figure 2-2. To avoid overestimating the rCBV by
including recirculation effects, the upper limit of the integrals can be modified to include only first-pass
CA contributions, or

∫

( )

∫

( )
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,

where tfp is the time at which reperfusion of the CA begins. However, performing the integration of
equation 2.44 will systematically underestimate the rCBV, as the result of neglecting the first-pass
concentration that is superimposed with CA recirculation shortly following tfp. Thompson et al. [141]
showed that a gamma-variate,
( )

(

)

(

)

,
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provided an excellent empirical description of the first-pass kinetics, where α, β, and κ are free model
parameters, and t0 is the bolus arrival time, which can be assumed or, more often, fitted as another
model parameter. This approach is illustrated in Figure 2-2, in which a gamma-variate was fitted to the
first-pass peak of a VIF. Integrating the resultant fitted gamma-variate in this way provides a means of
extracting first-pass kinetics without unnecessarily biasing the resultant measurement by purposely
neglecting or including concentration contributions that violate the assumptions of the system model.
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Figure 2-2. Contrast agent recirculation example. This plot shows a VIF contrast uptake curve with
the solid line representing a fitted gamma-variate and the black arrow specifying the characteristic
recirculation peak.

While this approach is used frequently to calculate the rCBV independent of rCBF, the requirement of a
non-linear fitting algorithm, especially with four free parameters, requires substantial computational
resources, and still requires the determination of a reperfusion cut-off, neglecting all data following the
cut-off when performing fits to equation 2.45.

2.1.4.2 Quantitative DSC-MRI – Acquisition and Analysis Strategies
When confined to intravascular spaces, the gadolinium based CAs, as discussed at the
beginning of section 2.1.4, can be used to affect the transverse relaxation rates of biological systems,
and in conjunction with a T2- or T2*-weighted imaging strategy and PK model allow investigation of the
relative vascular volume. As with the longitudinal relaxation rate, the presence of Gd affects the local
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transverse relaxation rate based on the T2 relaxivity, r2, of the CA, and can be, to a first order
approximation described by
,

2.46

where R2 is the resulting transverse relaxation rate of the sample and [Gd] is the CA concentration. In
addition to the increase in R2, Gd also alters the local bulk magnetic susceptibility resulting in relatively
large inhomogeneous local magnetic fields that interact with intra- and extravascular water protons,
inducing further dephasing beyond that of the R2 mechanisms. When using pulse sequences that fail to
refocus dephasing arising from local field inhomogeneities, the transverse relaxation rate is described
more completely by a superposition of relaxation mechanisms accounting for the thermal signal decay
(R2) and inhomogeneous field induced decay (R2’), represented mathematically as
,

2.47

from which an expression analogous to equation 2.46 can be written to describe the resultant relaxation
rate, namely
.

2.48

Intravascular accumulation of the CA modifies both the R2 and R2* relaxation rates, but, for compactness
and because the acquisitions of this work were T2*-weighted, R2* will be used exclusively in the
discussion to follow.
In the same manner as DCE acquisitions (section 2.1.3.2), a fast imaging sequence capable of
acquiring a volume of images every 1-2s is required to adequately estimate the temporal and spatial
distribution of the CA. Generally, SE or gradient recalled echo (GRE) echo planar imaging (EPI) sequence
is used to rapidly acquire T2- or T2*-weighted images, respectively, although other sequences have been
used [12]. Several pre-contrast phases are acquired to establish the steady-state baseline signal
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intensity, followed by another few minutes of cinematic image acquisitions. The resulting serial images
can then be used to estimate [Gd], which is, in turn, used to estimate rCBV.
Assuming that the introduction of CA negligibly impacts the proton density (i.e., S0 is constant)
and longitudinal relaxation rates (i.e., R10 is constant), then for simple GRE (or SE by removing the *
superscript) imaging sequence, the solution to Bloch’s equations can be written compactly as
(

( )

)

(

)

(

)
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where Ω is a constant, pulse sequence specific function incorporating constant imaging parameters such
as TE, TR, and the flip angle α. A similar expression can be easily written for the pre-contrast signal
intensity, Spre, resulting in an expression for [Gd] after performing some algebraic manipulations on the
ratio of pre- and post-contrast signal intensities and is given by

( )

(

( )

)
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Unlike the DCE acquisition strategies discussed previously (section 2.1.3.2), access to the CA
concentration is independent of the pre-contrast transverse relaxation rate, greatly simplifying
quantitative analysis. However, quantitation still requires the determination of a VIF or, using the
notation of section 2.1.4.1, Ca(t). Common measurement locations for the VIF include the cerebral
arteries (or some peripheral branch) and the internal carotid arteries [12].

2.1.4.3 Quantitative DSC-MRI – Additional Considerations
Perhaps the most important consideration in modeling DSC-MRI as described in this section
is the validity of assuming that the CA remains compartmentalized in the intravascular space. In fact, use
of the DCE-MRI pharmacokinetic models described in the previous section (2.1.3) relies heavily on the
assumption that the CA will extravasate, an assumption that is likely invalid in high-grade brain tumors.
Two unique issues face PK modeling under these conditions: R1 increases resulting from extravascular
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CA distribution will, at least partially, mask the associated R2* effects [142] and the extravasation of CA
will reduce intravascular [Gd] resulting in an underestimations of the rCBV. Kassner et al. [142] showed
that pre-loading the system with Gd effectively minimized the R1 shine-through, a viable solution to the
former issue. However, compensating for the rCBV underestimation requires the use of more
sophisticated PK models such as the first-pass pharmacokinetic model proposed by Johnson et al. [143].

2.2 Statistics
2.2.1

Measuring Agreement and Repeatability

One method used frequently to detect agreement between known values and measurements is
Bland-Altman analysis, which provides the limits of agreement (LOA), calculated by

〈 〉

(

)
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where <d> is the average of differences between, in this case, the estimated and actual PK parameters,

σ is the standard deviation of differences, and n is the number of samples [144]. This formulation
essentially provides the 95% confidence interval for normally distributed differences, where agreement
occurs when an application specific acceptable difference encompasses these limits. Another frequently
used method is the concordance correlation coefficient [145], or CCC for short, which estimates the
expected deviation from a perfect correlation line (i.e., slope of one and intercept of zero) and is given
by

(
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where σA and σE are the variance of the actual and estimated values, respectively, µA and µE are the
means of the actual and estimated values, respectively, and ρ is the Pearson correlation coefficient.

2.2.2

Logistic and Ordinal Regression

Logistic regression is a type of statistical classification technique that provides a means of
modeling a binary response, and can be considered a special case of ordered logistic regression or,
stated more succinctly, ordinal regression. These flexible models provide a means of modeling
categorical (ordinal) data, such as radiological response (partial response, stable disease, progressive
disease, etc.). In particular, ordinal regression allows multiple categories to be modeled simultaneously
through the assignment of categorical probabilities. Discussions herein were adapted from the text by
Johnson and Albert [146].
Let pi denote the probability of success for the ith observation, Xij denote the vector of
explanatory variables for the ith observation, and βj is the regression coefficient for the jth explanatory
variable. In the context of modeling ordinal data, failure and success can be restated as classification
into categories, say, C1 and C2, respectively. Using this nomenclature, the probability that the ith
observation falls in category C2 (success) can be written as
∑

(

),
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or more compactly, by indexing j such that j assumes all integer values between 0 and n, and Xi0 is one
for all values of i,
(

)

( ),

2.54

where F is known as the link function and Z is referred to as latent variable or latent trait. Link functions,
usually chosen from the class of cumulative density functions (CDF), map the latent variable’s range,
described in the argument of equation 2.54, to the interval (0, 1), providing a means of probabilistic

41

interpretation. Common link functions include CDFs of the normal, logistic, and log-logistic distributions,
and although the choice is somewhat arbitrary, the logistic distribution will provide the foundation for
this work. The CDF for the logistic distribution is given by
( )

.

2.55

After a link function has been selected and covariates are chosen, values of pi can be estimated from the
response of a training data set, and maximum likelihood estimation can be used to calculate the
regression coefficients. Predictions can then be performed on new data sets using the newly estimated
logistic model.
Latent variables, as introduced in equation 2.54, can be used to model unobservable traits, and,
moreover, provide a framework for intuitively extending the categorical response modeled by logistic
regression to more than two categories (i.e., ordinal regression). These traits provide a means of
determining the categorical response. Given some observation, the latent trait for that observation can
be modeled as
,
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where the error terms, ϵi, are assumed to be identically distributed according to the distribution of the
link function and are also assumed to be independent. Then for two categories, say C1 and C2 (failure or
success, respectively, as discussed previously for logistic models), the response can be written as

{

.
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This notion can be extended easily to accommodate k ordered categories by introducing category cutoffs, γc, resulting in the following response definition,
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{

2.58

,

where γ0 is defined to be negative infinity, a mere notational convenience. Defining the response in this
manner allows for the development of ordinal regression models.
To formulate ordinal regression in an analogous manner to logistic regression (equation 2.54),
the individual category probabilities must be computed. Since the response probabilities are
parameterized by the CDF F and the latent trait Z, the probability of attaining a particular category, say
category c, is simply the integral of the probability density function (the first derivative of the CDF)
between the cut-offs γc and γc-1, or, using the first fundamental theorem of calculus,
(

)

(

).
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By defining the cumulative probability of the cth category as
,

2.60

one can easily show, using equations 2.59 and 2.60, that a system of k-1 equations following the
operational form of the logistic regression described previously (i.e., equation 2.54) is given by
(

).

2.61

To avoid overparameterization of the model, the cut-off γ1 is fixed to zero, and all remaining cut-offs and
regression parameters are calculated using maximum likelihood estimation. If the observations are
assumed to be independent, then responses, yi, will follow a multinomial distribution, a generalization
of the binomial distribution (the distribution describing the response of logistic models).
In standard linear regression, the coefficient of determination or R2 is of considerable utility in
assessing the explanatory nature of the independent variable when defined as the fraction of explained
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model variance, and is often used a goodness-of-fit indicator. Nagelkerke [147], recognizing the utility of
R2, generalized the notion to encompass models such as ordinal regression. Let L(0) define the likelihood
of the null model (i.e., only model constants such as the category cut-offs and β0 are determined) and
L(β) be the likelihood of the full regression model (i.e., all cut-offs and regression coefficients are
calculated), then the coefficient of determination proposed by Nagelkerke [147] is given by
( ( ) ( ))
( )

̅

,
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where n is the number of observations, and can be interpreted analogously to the classical R2. In fact,
when applied to linear regression and the maximum likelihood estimate approach is equivalent to
ordinary least squares, the classical definition and that proposed by Nagelkerke give the same results.
Statistical classification techniques utilize a simple construction for performing predictions. Let
pi be the vector of probabilities for a k category ordinal regression model for which the category cut-offs
and regression coefficients have been determined, written mathematically as
(

),
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then the predicted category given by
̂

.

2.64

This succinct notation simply states that the predicted response for some new observation yields a
vector of probabilities pi for which the predicted classification is given by the category with the
maximum probability.

2.2.3

Cross-Validation

Cross-validation is a technique for assessing the generalizability of classification models, a
thorough discussion of which can be found in the text by Hastie et al. [148], for example. Given some set
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of training data, {Xij, Yi}, the goal of cross-validation is to determine the misclassification (or classification
error) rate on some larger set of data. If predictions are performed on some set of observations
different from the training set, the error rate for logistic/ordinal models discussed previously is given by
the ratio of misclassified predictions to the total number of observations, or written succinctly as
∑ (

̂) ,

2.65

where I(…) is the indicator variable for prediction misclassification. When a specific observation is
correctly classified, the indicator assumes a value of zero and one otherwise. Prediction accuracy can be
defined in a similar manner, or simply computed simply as 1-Err. In the context of this work, the goal of
cross-validation is two-fold: identify an appropriate model and assess that model’s performance.
K-fold cross-validation attempts to estimate the model prediction error rate by partitioning the
data into K subsets. By training the classifier on K-1 sets and performing predictions on the Kth test set
that was removed from the training set, an estimate of the classification error rate can be obtained. If K
is chosen to be the number of observations in the training data, then the so called leave-one-out (LOO)
cross-validation technique is attained, the focus of this work.
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Chapter 3 Assessing MR Equipment Bias and Variance

3.1 Introduction
Longitudinal assessment of quantitative imaging biomarkers for the purpose of treatment
response requires scrupulous assessment of measurement bias and variance attributable to the
equipment to ensure that the measured biological changes of interest are distinguishable from such
errors. The necessity of characterizing sources of equipment bias and variance, particularly those related
to quantitation, is of significant interest and importance as evidenced by numerous associated initiatives
from major organizations such as the American Association of Physicists in Medicine, Radiological
Society of North America, International Society of Magnetic Resonance in Medicine, and the National
Cancer Institute [73]–[76]. Within each of these organizations, several committees focusing on different
modalities and different aspects of image quantitation have been formed and are beginning to amass
data that consistently elucidate the need for longitudinal system assessment [78]–[80], [149].
To assess relaxometry, an important property intrinsic to biological tissues that is exploited in
contrast enhanced exams, and diffusion acquisition properties using physical phantoms, researchers
have proposed numerous approaches of varying complexity [150]–[153], including solutions and gels, in
addition to more complicated phantoms that attempt to mimic the actual physiological properties being
measured, such as the dynamic lesion phantom developed by Freed et al. [154] to assess DCE
acquisitions or the fiber phantom developed by Laun et al. [155] to assess DTI quantitation. To achieve
an optimal assessment of equipment bias and variance, sources of error, such as those introduced by
the manufacturing materials and manufacture processes, solution stabilities, and experimental
conditions (e.g., temperature), must also be mitigated where possible. With this goal in mind, the
primary design considerations for the phantoms proposed for these studies included: easily
reproducible manufacturing procedures, non-volatile chemicals, measurement values representative of
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Figure 3-1. DCE and ADC phantom schematics. Axial cross-sectional schematic representation of the
DCE (left) and ADC (right) phantom (units: cm). The DCE phantom inner ring (red) contains 8
solutions representative of VIF response (R1: 1.05-41.86 s-1) while the outer ring (blue) contains 8
solutions representative of tissue response (R1: 0.97-7.84 s-1). The ADC phantom contained vials with
various sucrose concentrations (10 to 45 %w/w); the lowest sucrose concentration was placed at the
center.

those found in vivo, long-term solution stability, well characterized temperature dependences, and
reproducible acquisition strategies. Phantoms matching these criteria were designed and manufactured
with the primary purpose of assessing equipment related variances using clinically relevant diffusion and
contrast-enhanced acquisitions.

3.2 Phantom Design
3.2.1

DCE Phantom

DCE acquisitions are designed to capture dynamic processes and, through modeling, estimate
physiological parameters. Currently, no viable dynamic phantom capable of mimicking these processes
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is available despite a recent proof-of-concept dynamic phantom [154]. Therefore, the approach taken in
this work focused on quantifying variances in the measurement of R1 relaxation rates and propagating
those measured variances to the estimation of PK parameters through simulated data using a static
phantom consisting of a large compartment filled with a homogeneous fill solution and several smaller
compartments with solutions having a range of R1 values. To adjust the R1 values, NiCl2 was used as a
paramagnetic doping material. As an R1 altering dopant, NiCl2 is approximately independent of magnetic
field strength for common clinical magnets (i.e., 0.2-4.0T) and temperature, ideal properties for
solutions used to estimate equipment bias and variance.
A schematic of the DCE phantom is shown Figure 3-1. The cylindrical phantom was constructed
from a polycarbonate cylinder measuring 20 cm in diameter with a depth of 12 cm and featured a
removable lid for installing various vials and a threaded plug providing access to the fill solution for
temperature measurements. Using an NiCl2 relaxivity of 0.62 mM-1s-1 [156], [157], theoretical [NiCl2]
values were calculated for a range of relaxivities representative of expected in vivo gadolinium
concentrations occurring during the course of a DCE study in a tissue compartment (R1: 0.67-7.54 s-1)
and a vascular compartment (R1: 0.75-41.53 s-1). Two batch solutions, one for each of the highest tissue
and vascular R1 values, were prepared using degased, deionized water. Serial dilutions of these batch
solutions were performed to achieve the theoretical [NiCl2] listed in Table 3-1. These solutions were
poured into 30 mL sealing, polypropylene copolymer, centrifuge tubes (Sigma-Aldrich, USA), placing the
tissue [NiCl2] solutions at the outer radius with R1 values increasing in the clockwise direction and the
representative vascular vials at the inner radius with R1 values decreasing in the clockwise direction. The
remaining volume of the phantom was filled with a 30 mM [NaCl] solution to simulate coil loading by a
patient and to minimize static, magnetic field inhomogeneities [158].

3.2.2

ADC Phantom
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The ADC phantom is represented schematically in Figure 3-1. Similar to the DCE phantom, this
phantom was constructed from polycarbonate with an exterior diameter of 20 cm and depth of 12 cm,
featuring the same removable lid and threaded plug design. Seven sucrose solutions, 10, 20, 25, 30, 35,
40 and 45 %(w/w), were used to achieve ADC values ranging from approximately 0.5 to 1.7x10 -3 mm2/s,
which encompass reported ADCs in normal and tumor tissues [159]–[161]. These values were
determined by estimating a linear fit to data reported by Laubach et al. [153]. Solutions were prepared
by stirring the appropriate weight of sucrose (≥99.5%, Sigma-Aldrich, USA) with degased, deionized
water, adding sodium azide (3 mg/mL of H20) to all vials to prevent alteration of the desired ADC values
by microbial growth. These solutions were then poured into 50 mL polypropylene centrifuge tubes
(Corning®, USA), and the caps were glued shut to minimize exchange of sucrose between the fill solution
and centrifuge tubes. The 10 %(w/w) vial was placed in the center with all other vials distributed in
increasing concentration in a counter-clockwise arrangement. In addition to the 30 mM NaCl fill
solution, a low concentration (165 mg/L) of MnCl2 was added to reduce the T2 of the fill solution to
approximately 30 ms, bringing the measured signal intensity close to that of background and thus
minimizing image artifacts resulting from the fill solution signal.
Tissue Compartment
Vascular Compartment
-1
Vial Number
R1 (s )
[NiCl2] (mg/L)
R1 (s )
[NiCl2] (mg/L)
1
0.97
139.4
1.05
156.8
2
1.24
197.1
2.93
548.7
3
1.63
278.7
6.86
1371.8
4
2.19
394.2
11.86
2416.9
5
2.97
557.4
17.86
3671.1
6
4.07
788.3
24.86
5134.3
7
5.63
1114.8
32.86
6806.6
8
7.84
1576.6
41.86
8687.8
Table 3-1. DCE phantom [NiCl2] and theoretical R1 values. R1 ranges and corresponding [NiCl2]
-1

theoretical calculations assuming r1 = 0.62 mM-1s-1 and R10 = 0.3s-1. Note that neither r1 nor R10 were
quantified prior to phantom manufacture.
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3.3 Methods
3.3.1

MR Acquisition Protocols

Assessing the equipment longitudinal variance was accomplished by performing a single set of
same day repeatability measurements in combination with ongoing weekly quantitative acquisitions
using the ADC and DCE phantoms on a 1.5T GE HDxt scanner and 3.0T GE MR750 scanner. Where
possible, acquisition parameters for these phantom studies were matched to corresponding clinical
protocols. To minimize variances due to variations in temperature, the phantoms were stored in the
scanner room overnight, allowing equilibration between the fill solution and scanner room temperature.
Additionally, the temperature of the phantom fill solution was measured prior to each imaging session.
Following the temperature measurements, the DCE phantom was scanned first, followed by the ADC
phantom.
The imaging protocol for the DCE phantom included, on a weekly basis, VFA R1 measurements
and a full DCE acquisition. The VTI R1 measurements were performed once a month. Each phantom was
set up on edge in the RF coil, aligning the vertical alignment laser to the center of the set screw between
the tissue vials with R1 values of 0.67 and 0.94s-1 and ensuring that the phantom was level. At each
scanner, one set of three short-term measurements was acquired to establish same day variance, which
included an initial acquisition per protocol with VTI R1 measurements followed by two more full
acquisitions without the VTI acquisition. Performing these measurements was accomplished by setting
the scanner to research mode, which allowed varying the user control variables opflip and opti for VFA
and VTI acquisitions, respectively. To ensure machine settings, such as center frequency, RF gains, and
gradient shims remained constant for serial relaxometry measurements, a manual pre-scan was
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performed after downloading each new scan flip angle or TI value and before acquiring any images. Scan
parameters are summarized in Table 3-2.
Multi-slice diffusion weighted imaging and diffusion tensor imaging data were acquired weekly
from the ADC phantom. Phantom set up consisted of situating the phantom in the RF coil such that the
cylinder’s edge rested on the support pad of the coil, rotating the 20 %(w/w) sucrose vial such that the
compartment was roughly aligned midway between 12 and 3 o’clock, and ensuring that the phantom
was level. Diffusion-weighted images were then acquired in three orthogonal planes aligned with the

Coil:
Sequence:
User CVs:
TE (ms):

TI (ms):

TR (ms):
ETL:
BW (kHz):
NEX:
Flip Angle (deg.):

VFA
8CH Brain
(32 CH Brain)
3D FSPGR
Turbo=0
1.4 (1.5)

DCE
8CH Brain
(32 CH Brain)
3D FSPGR
Turbo=2
1.2 (1.3)

DWI
8CH Brain
(32 CH Brain)
EPI
ASSET=2, DSE
82.7 (81.7)

DTI
8CH Brain
(32 CH Brain)
EPI
ASSET=2, DSE
82.7 (81.7)

---

---

5.7 (4.2)
N/A
+/-62.5
1

VTI
8CH Brain
(32 CH Brain)
FSE-XL
--8.8
50, 75, 100,
125, 150, 250,
500, 1000,
1500, 2000,
3000
6000
4
+/-31.25
1

---

---

5.8 (5.4)
N/A
+/-62.5
4
2, 5, 10, 15,
20, 25, 30

10000
N/A
+/-250
4

10000
N/A
+/-250
1

30

90

90

90

0, 250, 500,
b-value (s/mm ):
------750, 1000,
0, 1200
1250
FOV (cm):
24
24
24
24
24
Phase FOV (%):
1
0.8
1
1
1
Sl. Th. (mm):
5
3
8 (7)
5 (3.5)
5 (3.0)
Gap Th. (mm):
------1.5 (0.0)
1.5 (0.0)
Num. of Slices:
16
16
1
16
16
Matrix:
256x160
256x160
256x160
96x128
96x128
Table 3-2. DCE and ADC phantom protocol acquisition parameters. Parenthetical values represent the
2

acquisition parameters at 3.0T. For the DWI and DTI acquisitions, the number of diffusion encoding
directions was 3 and 27, respectively. Abbreviations: Sl. = Slice, Th. = Thickness, DSE = dual spin echo.
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major axes of the encoding gradients (i.e., R-L, A-P, and S-I). The diffusion tensor acquisitions used a 27
direction-encoding schema. Neither pulse sequence required user input to acquire multiple b-values as
was the case with R1 measurements. Protocol parameters for the acquisition of ADC phantom diffusion
data are summarized in Table 3-2.
Laubach et al. [153] noted a rapid decrease in T2 values with increasing concentration of
sucrose, making T2 characterization of the ADC phantom desirable. In an effort to confirm this result, T2
measurements were performed on the 3.0T system described previously using a multiple echo time
(n=4) acquisition. In addition to these measurements, T2 was also quantified using a 4.7T Bruker
BioSpec® scanner with S057 gradients and a 35 mm inner diameter birdcage coil with a 32 echo CarrPurcell Meiboom-Gill (CPMG) SE acquisition.

3.3.2

Equipment Variance Quantitation

Following image acquisition as described in section 3.3.1, all images were transferred via file
transfer protocol, in DICOM format, to a Linux workstation with an 8 core Intel® Xeon® E5640 CPU
operating at 2.67GHz. Images from the individual series (e.g., VFA or DWI) were then imported into the
QUATTRO environment, which automatically detected the series type (e.g., VFA or DWI), sorted the
images by slice location into stacks containing each of the varied imaging parameters (e.g., flip angle or
b-value), and extracted, from the DICOM headers, pertinent acquisition parameters necessary for
modeling the data and computing the image biomarker results. Uniquely named, elliptical ROIs were
then manually defined within the individual phantom compartments and voxel signal intensities were
averaged for each ROI at each series point (e.g., at each flip angle). For 3D or multi-slice acquisitions,
these ROIs were propagated to all slices, ensuring that the ROIs remained centered within the
compartment of interest by manually adjusting the ROI placement as needed to account for minor
rotations that inevitably occurred during setup. Care was also taken to ensure image artifacts, such as
partial volume averaging, Gibb’s ringing, and N/2 ghosting, were avoided. The resulting mean signal
52

intensities for each acquisition in the series were fitted to an appropriate model using a QUATTRO script
to estimate and track model parameters and a goodness of fit parameter, the coefficient of
determination. For the models discussed in the following subsections, the LOA and CCC values, as
discussed in section 2.2.1, were computed to assess agreement between estimated and theoretical
values where possible.

3.3.2.1 R1 Variance
VFA estimation of R1 was performed by fitting the averaged signal intensities from each ROI
as a function of flip angle to the well-known analytical Bloch equation solution, as discussed in section
2.1.1, for a spoiled gradient echo sequence given by equation 2.19. Bland-Altman [144] and correlation
plots were produced to compare R1 estimates with the theoretical calculations. Since these
measurements were acquired with a volume acquisition, variation of R1 was also characterized as a
function of distance from the magnet isocenter in the slice direction by averaging longitudinal
measurements and normalizing those measurements to the corresponding R1 estimate at isocenter.
VTI estimation of R1 was accomplished by a two-step procedure. First, to avoid introducing bias
in the modeling caused by artificially increased signal intensities near the null point [12], polarity
restoration was performed on the magnitude image signal intensities averaged from each ROI using a
simple algorithm described in section 4.2.1. The resulting polarity corrected signal intensities were then
fitted to the three-parameter signal intensity relationship given by equation 2.22, and Bland-Altman and
correlation plots were produced for comparison with theory.

3.3.2.2 DCE Variance
Estimating PK parameter variance from the static DCE phantom data was accomplished by
fitting simulated tissue uptake curves using a VIF derived from patient brain data [162]. One-hundred
fifty unique combinations of Ktrans, ve, and vp were chosen to generate the tissue uptake curves from the
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three parameter general kinetic model [110]. The values for those three parameters were selected from
the sets {0.02, 0.05, 0.1, 0.2, 0.35} min-1, {0.05, 0.1, 0.2, 0.5}, and {0.05, 0.1, 0.2, 0.5}, respectively. To
map meaningful estimates of variance in T1 measurements to the respective PK parameter, the means
and standard deviations of T1 measurements for each compartment were provided to a random number
generator to produce random fluctuations in the synthetic VIF and tissue uptake curve. Because the
simulated curves represent discrete samples from a continuous distribution of ΔR1 values, and because
the number of ΔR1 samples from the phantom is limited, a binning of ΔR1 was performed to provide a
distribution for all values of ΔR1. In other words, for synthesized [Gd] values, x, on a given tissue uptake
curve, the values falling between the ith and ith+1 tissue vials’ ΔR1 values were randomly sampled from a
normal distribution of mean x and standard deviation σi, where σi is the estimated standard deviation
from the T1 measurement distribution of the ith vial and i = {1, 2, 3,…, 7}. This process was repeated for
the VIF to produce noisy VIF values for simulations. To ensure that the random number generator was
appropriately configured, longitudinal T1 measurement distributions for every compartment were tested
for normality using a single sample Kolmogorov-Smirnov goodness-of-fit hypothesis test [163] with
significance level of 5%. All tests failed to reject the null hypothesis, suggesting that the data were, to a
good approximation, normally distributed.
For each combination of PK parameters, 10,000 unique random tissue uptake curves and VIFs
were simulated. Finally, these noisy synthetic tissue and VIF [Gd] concentration measurements were
fitted using a three-parameter generalized kinetic model to estimate the PK parameters. To avoid
introducing known effects, namely additional bias and variance of temporally undersampled dynamic
curves [164], [165], allowing isolation of equipment related variance, high temporal resolution (50 ms
sampling) versions of the tissue uptake and VIF concentration curves were used. LOA and CCC values
were computed for the estimated pharmacokinetic parameters to assess the agreement between
estimated and actual values.
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3.3.2.3 ADC Variance
Estimation of the ADC values was performed by fitting the averaged signal intensities from
each ROI to the intravoxel incoherent motion model equation 2.16 as described in section 2.1.1. This
simplified version of the IVIM model ignores the pseudo-diffusion coefficient, perfusion fraction, and
diffusion kurtosis terms of the full model since the physical processes represented by these terms are
not captured in the simple sucrose solution ADC phantom. The exponential term containing the
transverse relaxation constant was absorbed into the

parameter since

was held constant for all b-

value acquisitions. This model was used to perform parameter estimation from the DWI images, where
the images were first averaged over all three orthogonal acquisitions before modeling. DTI images
transferred to a GE Advantage Windows Workstation running FuncTool (GE Healthcare, Waukesha, WI,
version 4.5), which was used to compute ADC and FA maps. Both acquisition strategies were used to
analyze the effect of off-isocenter parameter estimates as described previously for the VFA acquisitions.

3.4 Results
3.4.1

Equipment Variance

The ADC and DCE phantoms were manufactured as described in Section 3.2 and the acquisition
protocols were created and stored on the respective 1.5T or 3.0T scanner as described in Section 3.3.1.
MATLAB scripts were created to sort and assemble images into directories by date, phantom name, and
series number, which allowed the import utility of QUATTRO to easily assemble exams for quantitation.

3.4.1.1 R1 Variance
Longitudinal R1 results estimated from a single central slice are summarized in Table 3-3,
showing substantially better repeatability for R1 measurements at 1.5T compared with the
corresponding measurements at 3.0T, with coefficients of variation ranging from 2 to 3.2% and from 6.4
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to 10.2% at 1.5 and 3.0T, respectively. VFA-estimated R1 values measured from a single slice in the
center of the phantom exhibited minimal bias compared with the theoretical values for measurements
made at 1.5T as shown in Figure 3-2, while those same measurements at 3.0T were consistently overestimated, particularly in the VIF compartments.
1.5T VFA

3.0T VFA

1.5T VTI

-1

-1

-1

3.0T VTI

R1 (s ) COV (%) R1 (s ) COV (%) R1 (s ) COV (%) R1 (s-1) COV (%)
VIF-1
VIF-2
VIF-3
VIF-4
VIF-5
VIF-6
VIF-7
VIF-8

1.0
2.7
6.4
11.5
17.4
24.7
32.1
40.3

2.4
2.4
2.3
2.2
2.0
2.0
2.5
3.2

0.7
2.1
5.3
9.4
14.0
18.9
24.4
30.8

7.2
8.3
7.2
6.4
6.7
7.4
7.6
7.6

1.0
2.9
6.8
10.5
17.5
24.6
32.8
41.7

0.6
0.6
0.8
2.4
0.8
1.0
1.3
1.8

1.1
3.0
7.2
11.8
18.8
27.1
36.5
48.5

1.6
2.3
1.5
3.4
1.0
2.7
4.0
8.2

Tissue-1
Tissue-2
Tissue-3
Tissue-4
Tissue-5
Tissue-6
Tissue-7
Tissue-8

0.9
2.7
0.8
10.2
1.0
1.0
1.0
1.4
1.2
2.6
1.0
9.4
1.2
0.6
1.3
3.0
1.6
2.8
1.3
8.1
1.6
0.5
1.7
1.2
2.0
2.6
1.7
8.0
2.1
0.6
2.3
0.5
2.8
2.3
2.3
8.2
2.9
0.8
3.0
0.7
3.8
2.5
3.4
7.8
3.9
0.9
4.2
1.1
5.2
2.7
4.9
7.0
5.5
1.1
5.8
0.9
7.6
2.3
7.5
7.5
7.6
0.7
8.2
1.3
Table 3-3. Summary of the DCE phantom longitudinal R1 measurements. Measured R1 values in s-1
averaged over all repeatability measurements using a VFA technique (left) and VTI technique (right).
Values for the centrifuge tubes containing the VIF sequence are in the top half of the table, while the
representative tissue values are in the bottom half of the table.
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Measured R1 (s-1)
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0.0
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Figure 3-2. Comparison of VFA R1 estimation with theory. Bland-Altman plots (top) of the
longitudinally averaged VFA R1 measurements vs. theoretical R1 values at 1.5T (left) and 3.0T (right).
The 8 VIF (squares) and tissue (diamonds) compartments were given different markers for clarity and
the dashed lines are the limits of agreement. Correlation plots (bottom) are shown for comparison
with the linear regression and corresponding coefficient of determination for 1.5T (left) displayed
above the data and that for 3.0T (right) displayed below the data.
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VFA R1 relaxometry techniques are known to suffer inaccuracies in parameter estimation as a
result of flip angle calibration errors and/or spatial heterogeneity in the transmitted B1 field [104], [166],
[167]. At higher field strengths, spatial heterogeneity of the B1 fields, in particular, increasingly biases R1
measurements as a function of position due to reduced RF penetrability and dielectric resonance
effects. In brain applications, dielectric resonance is especially pronounced in objects roughly the size of
a human head (i.e., the DCE phantom) [12]. This would imply larger biases in R1 estimates at the center
of the phantom, where the VIF centrifuge vials are positioned, as is clearly demonstrated in Figure 3-2.
In combination, these effects explain the larger observed bias and variance in longitudinal
measurements at 3.0T when considering uncertainties such as phantom setup and flip angle
calibrations.
Single slice, VTI-estimated R1 values exhibited excellent longitudinal repeatability, with
coefficients of variation ranging from 0.5 to 2.4% at 1.5T and from 0.5 to 6.9% at 3.0T as summarized in
Table 3-3. Note that by neglecting a single set of outlier data acquired at 3.0T on February 24, 2013, COV
ranges between different field strengths become equivalent. The cause of this deviation was most likely
an incorrect acquisition setting; a BW of +/-62.5 kHz was used as opposed to +/-31.25 kHz as prescribed
in the protocol. In addition to improved repeatability over VFA parameter estimation, the VTI R1
estimates agreed with theory for the VIF [NiCl2] sequence at both field strengths (see Figure 3-3),
although a trend is still discernible in the VIF [NiCl2] sequence at 3.0T. This trend, which is consistent in
the VIF and tissue vials, might suggest a slight field strength dependence of the [NiCl2] relaxivity, r1.
Additionally, these results further corroborate the notion that the less repeatable and more biased R1
estimates using a VFA acquisition at 3.0T were the result of transmit RF inhomogeneities. While these
issues would still be present in VTI acquisitions, the resulting bias and variance in R1 measurements are
effectively decoupled from the flip angle because long TR values were used, which allows near full
recovery of the longitudinal magnetization.
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In addition to single slice measurements, estimates of R1 were tracked on each slice of the
volume acquisition. Figure 3-4 through Figure 3-7 displays the relationship between R1 and the slice
distance from isocenter in the superior-inferior direction, omitting the first and last slices of the volume.
In this range of slices, R1 values deviated from the corresponding measurements on the slice at isocenter
from -11.5 to 7.2% at 1.5T and -15.4 to 26.6% at 3.0T for all vials. Including all slices, however, creates
substantially larger deviations: -76.8% at 1.5T and -74.6% at 3.0T. The additional deviation introduced by
including the end slices is the result of non-ideal RF excitation of the imaging volume in the slice
encoding direction and off-resonance effects.
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Figure 3-3. Comparison of VTI R1 estimation with theory. Bland-Altman plots (top) of the
longitudinally averaged VTI R1 measurements vs. theoretical R1 values at 1.5T (left) and 3.0T (right).
The 8 VIF (squares) and tissue (diamonds) compartments were given different markers for clarity and
the dashed lines are the limits of agreement. Correlation plots (bottom) are shown for comparison
with the linear regression and corresponding coefficient of determination for 1.5T (left) displayed
above the data and that for 3.0T (right) displayed below the data.
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Figure 3-4. 1.5T VIF R1 dependence as a function of distance from isocenter in the I-S direction.
Plots of the VIF [NiCl2] sequence R1 estimates normalized to the corresponding measurements on
the slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged
over all longitudinal acquisitions at 1.5T. Data from the two most superior and two most inferior
slices were omitted to ensure the imaging volume was matched to the corresponding 3T data. For
visualization purposes, a shape-preserving smooth interpolant was used. Error bars were omitted
because limits were so small that the error markers were indistinguishable from the data markers.
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Figure 3-5. 3.0T VIF R1 dependence as a function of distance from isocenter in the I-S direction.
Plots of the VIF [NiCl2] sequence R1 estimates normalized to the corresponding measurements on
the slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over
all longitudinal acquisitions at 3.0T. For visualization purposes, a shape-preserving smooth
interpolant was used. Error bars were omitted because limits were so small that the error markers
were indistinguishable from the data markers.
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Figure 3-6. 1.5T tissue R1 dependence as a function of distance from isocenter in the I-S direction.
Plots of the tissue [NiCl2] sequence R1 estimates normalized to the corresponding measurements on
the slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over
all longitudinal acquisitions at 1.5T. Data from the two most superior and two most inferior slices
were omitted to ensure the imaging volume was matched to the corresponding 3T data. For
visualization purposes, a shape-preserving smooth interpolant was used. Error bars were omitted
because limits were so small that the error markers were indistinguishable from the data markers.
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Figure 3-7. 3.0T tissue R1 dependence as a function of distance from isocenter in the I-S direction.
Plots of the tissue [NiCl2] sequence R1 estimates normalized to the corresponding measurements on
the slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over
all longitudinal acquisitions at 3.0T. For visualization purposes, a shape-preserving smooth
interpolant was used. Error bars were omitted because limits were so small that the error markers
were indistinguishable from the data markers.

3.4.1.2 DCE Variance
LOA and CCC values calculated from the simulations performed using the R1 variance
estimated from the VFA and VTI data are summarized in Table 3-4. In all cases, the CCC was, for all
intents and purposes, unity, suggesting excellent agreement between the estimated parameters and the
actual values. Moreover, the limits of agreement, essentially two standard deviations, for the estimated

64

values of Ktrans, ve, and vp, were essentially zero. With respect to expected changes in tissue resulting
from treatment, the parameter noise introduced by the reproducibility of relaxometry measurements
represents insignificant variation in T1-weighted DCE biomarkers. For example, Hawighorst et al [70], in a
study of intracranial meningiomas treated with conformal radiation therapy, found a significant
decrease in kep (Ktrans/ve) on the order of 50% in patients responding to the treatment (n=13) and a
median increase greater than 500% in non-responders (n=4). Gutin et al. [168] found a significant
decrease in Ktrans (approximately 31%) following the administration of a single cycle of bevacizumab in
patients exhibiting some radiographic response. The symmetry observed in all LOA values suggests
negligible bias introduced by noise, which is confirmed by mean percentage error of approximately
7.6x10-3 % for all pharmacokinetic parameters using the variance estimated from VFA repeatability and
6.06x10-3 % for the VTI simulations. Overall, the results of these simulations suggest that the level of
error introduced by variation in R1 measurements is insignificant with respect to expected changes
resulting from treatment.

trans

K
(min-1)
Lower LOA
1.5T Upper LOA
CCC

VFA Simulations
ve

-8.77x10-4
8.06x10-4
1.000

-3.17x10-3
3.21x10-3
1.000

vp

trans

K
(min-1)

VTI Simulations
ve

vp

-2.14x10-4 -9.61 x10-4 -3.48 x10-3 -2.36 x10-4
2.31x10-4 8.72 x10-4 3.53 x10-3 2.56 x10-4
1.000
1.000
1.000
1.000

Lower LOA -8.65 x10-4 -3.20 x10-3 -2.14 x10-4 -9.66 x10-4 -3.47 x10-3 -2.37 x10-4
3.0T Upper LOA 7.95 x10-4 3.24 x10-3 2.30 x10-4 8.78 x10-4 3.53 x10-3 2.58 x10-4
CCC
1.000
1.000
1.000
1.000
1.000
1.000
Table 3-4. Analysis of PK parameters simulated from R1 variance. Lower/upper limits of agreement
and concordance correlation coefficient as calculated from the simulated PK parameter estimates for
levels of ΔR1 variance at 1.5T (top) and 3.0T (bottom).
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3.4.1.3 ADC Variance
When measured at a single slice at the center of the imaging volume, DWI-based ADC
estimates exhibited good longitudinal reproducibility at both 1.5 and 3.0T, with coefficients of variation
ranging from 3.4 to 6.8% and 1.5 to 19.4%, respectively (see Table 3-5). Again, neglecting the lone
outlier datum of the longitudinal ADC estimates at 3.0T brings the maximum range of coefficients of
variation to 4.8%, comparable with corresponding measurements at 1.5T. This discrepancy in
reproducibility most likely stems from the differences in the signal-to-noise ratio of the two data sets.
More specifically, the observed lower signal-to-noise ratio of data acquired at 3.0T. In addition to
acquisition differences, sucrose concentration dependent T2 values also created SNR dependencies of
the repeatability as seen in the trend of increasing coefficients of variation with increasing sucrose
concentration, although not as pronounced in the measurements made at 1.5T because of the higher
overall SNR in those data. Laubach et al. [153] reported a rapid decrease in the solution T2 value with
increasing concentration of sucrose, with T2 values as low as 50ms for a 30%(w/w) sucrose solution. T2
values of the ADC phantom sucrose solutions were quantified with a multiple-echo spin echo acquisition
at 3.0T and 4.7T to extend the results of that previous work, and to confirm the rapid signal loss as a
function increasing sucrose concentration; results are summarized in Figure 3-8. With large effective
values (~80ms), the dramatic decrease in T2 can clearly be considered a dominate factor in the
decreased repeatability of higher concentration vials.
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1.5T DTI
3.0T DTI
COV
ADC
COV
ADC
COV
(%) (x10-3 mm2/s) (%) (x10-3 mm2/s) (%)
1.75
3.6
1.68
1.2
1.5
1.40
3.0
1.38
1.6
1.6
1.17
3.3
1.11
3.5
2.0
0.97
3.6
0.83
5.3
3.0
0.78
4.0
0.59
7.1
3.7
0.64
4.8
0.47
11.2
4.8
0.51
6.6
0.33
18.3
19.4
Table 3-5. Summary of the diffusion phantom longitudinal ADC measurements. Measured ADC
1.5T DWI
3.0T DWI
Sucrose
ADC
COV
ADC
(%w/w) (x10-3 mm2/s) (%) (x10-3 mm2/s)
10
1.71
3.4
1.69
20
1.39
4.1
1.38
25
1.17
3.7
1.12
30
0.96
3.7
0.85
35
0.79
4.1
0.61
40
0.64
4.7
0.46
45
0.49
6.8
0.29

(x10-3 mm2/s) values averaged over all repeatability measurements using a DWI technique (left) and
DTI technique (right) for sucrose concentrations ranging from 10% to 45% (top to bottom).

Phantom temperatures were measured prior to each set of image acquisitions. At 1.5T, the
average temperature was 20.5°C, ranging from 16.0°C to 23.9°C with a COV of 7.5%, whereas the
average temperature at 3.0T was 20.9°C with a minimum of 20.1°C and maximum of 22.6°C with a COV
of 2.4%. This larger difference in the phantom temperature variability prior to measurements at 1.5T
explains the less repeatable measurements, as clearly shown in the COVs, for vials containing low
concentrations of sucrose (≤35%) compared with the corresponding 3.0T measurements.
Reproducibility of ADC estimates acquired with DTI in a single central slice exhibited similar
trends as those estimates made with a DWI technique and the results are summarized in the right half of
Table 3-5. The range of coefficients of variation at 1.5T was 3.0 to 6.6% and at 3.0T was 1.2% to 18.3%,
where the trend of increasing coefficients of variation with increasing sucrose concentration is again
apparent. Fractional anisotropy estimates in a single central slice were less reproducible compared with
ADC values, with coefficients of variation ranging from 6.4 to 25.5% at 1.5T and 18.2 to 26.3% at 3.0T.
These results, while suggestive of poor fractional anisotropy reproducibility, more likely represent the
fact that there were miniscule fluctuations in a material with isotropic diffusion (i.e., FA=0), which
results in disproportionately large apparent variance. In addition to comparable reproducibility, the two
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methods provided good agreement according to a Bland-Altman analysis of data measured at a single
central slice where no regression coefficients of lines fitted to the difference between DWI and DTI
measurements deviated significantly from 0 (p>0.20 for coefficients at 1.5 and 3.0T).
Analysis of axial ADC measurements as a function of slice location relative to isocenter showed
deviations in magnitude from 7.9% at 1.5T and 35.2% at 3.0T, as illustrated in Figure 3-9 and Figure
3-10. For volumes acquired at 1.5T, only the portion that overlapped with the 3.0T acquisitions were
considered in this analysis since, in a clinical environment, this region would contain the pertinent
imaging biomarker information. DTI estimates of ADC, summarized in Figure 3-11 and Figure 3-12,
deviated from the isocenter slice normalized value by 4.5% at 1.5T and 26.8% at 3.0T, respectively.
Fractional anisotropy deviated substantially more compared with ADC estimates (as easily seen in Figure
3-13 and Figure 3-14) as the distance from isocenter increased, with deviations as large as 66.2% at 1.5T
and 93.3% at 3.0T.
Bland-Altman analysis was also performed to compare the ADC and FA estimates between the
two scanners, which yielded significant non-zero regression coefficients (P<0.01) for ADC estimates,
both DWI and DTI, and non-zero regression coefficients approaching significance (P<0.04) for FA
estimates. As stated previously, the differences in signal-to-noise ratios resulting from thinner slices at
3.0T and the already low signal, particularly in vials with high sucrose concentrations (i.e., >25%), results
in noise-dominated signal, which is known to underestimate ADC values [169]–[171]. When considering
the lower concentration compartments (i.e., ≤25%), the percent difference between 1.5T and 3.0T data
was approximately 5% or less for all ADC estimates.
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Figure 3-8. Sucrose solution T2 values. Measured T2 values at 3.0T (diamonds) and 4.7T (squares).
The large difference in values between the two field strengths stems for the acquisition details,
namely, only 4 echoes were used to acquire measurements at 3.0T compared to the 24 echoes used
at 4.7T. The number of echoes was limited by the acquisition pulse sequence at 3.0T. Also, the T2
value at 4.7T for the 45% vial was extrapolated since no data were acquired for that vial.
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Figure 3-9. 1.5T DWI ADC dependence as a function of distance from isocenter in the I-S direction.
Plots of ADC measured at 1.5T using DWI normalized to the corresponding measurements on the
slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over all
longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a shapepreserving smooth interpolant was used for visualization purposes. Error bars were omitted because
the error markers were indistinguishable from the data markers.
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Figure 3-10. 3.0T DWI ADC dependence as a function of distance from isocenter in the I-S
direction. Plots of ADC measured at 3.0T using DWI normalized to the corresponding measurements
on the slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged
over all longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a
shape-preserving smooth interpolant was used for visualization purposes. Error bars were omitted
because the error markers were indistinguishable from the data markers.
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Figure 3-11. 1.5T DTI ADC dependence as a function of distance from isocenter in the I-S direction.
Plots of ADC measured at 1.5T using DTI normalized to the corresponding measurements on the
slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over all
longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a shapepreserving smooth interpolant was used for visualization purposes. Error bars were omitted because
the error markers were indistinguishable from the data markers

72

Figure 3-12. 3.0T DTI ADC dependence as a function of distance from isocenter in the I-S direction.
Plots of ADC measured at 3.0T using DTI normalized to the corresponding measurements on the
slice at isocenter vs. distance from isocenter in the I-S (negative-positive) direction averaged over all
longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a shapepreserving smooth interpolant was used for visualization purposes. Error bars were omitted because
the error markers were indistinguishable from the data markers
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Figure 3-13. 1.5T FA dependence as a function of distance from at isocenter in the I-S direction.
Plots of FA measured at 1.5T normalized to the corresponding isocenter slice measurement as a
function of distance from isocenter in the I-S (negative-positive) direction averaged over all
longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a shapepreserving smooth interpolant was used for visualization purposes. Error bars were omitted because
limits were so small that the error markers were indistinguishable from the data markers.
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Figure 3-14. 3.0T FA dependence as a function of distance from at isocenter in the I-S direction.
Plots of FA measured at 3.0T normalized to the corresponding isocenter slice measurement as a
function of distance from isocenter in the I-S (negative-positive) direction averaged over all
longitudinal acquisitions. Data volumes were matched to 3.0T acquisition coverage and a shapepreserving smooth interpolant was used for visualization purposes. Error bars were omitted because
limits were so small that the error markers were indistinguishable from the data markers.

3.5 Discussion
Quality assurance, particularly on machines used for the assessment of treatment response,
remains a crucial component of any study employing quantitative imaging data. Documenting
quantitative stability, especially following hardware/software upgrades, provides confirmation that
longitudinal patient measurements are minimally impacted by scanner bias and variance. Additionally,
performing such measurements at multiple sites provides the framework for designing and executing
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data harmonization from multi-center trials. This study aimed to quantify the longitudinal reproducibility
of quantities derived from diffusion and DCE imaging acquisitions at scanner field strengths commonly
used, namely 1.5 and 3.0T, and under normal operating conditions.
Two scanners, one used for routine clinical imaging (1.5T) and one used for research purposes
only (3.0T), were monitored over the course of 10 months, during which weekly acquisitions of
relaxometry and diffusion data were performed and the resulting quantitative imaging biomarkers were
tracked. Axial slice position dependences were also tracked for these quantities. In general, T1
measurements agreed well with theoretical calculations based on published relaxivities [156], [157] and
ADC estimates were consistent with previously published results [153]. In addition to providing
longitudinal stability, these phantoms were easily manufactured requiring only a scale with milligram
accuracy, a stirrer, and a source of degased, deionized water, making these phantoms ideal candidates
for assessing equipment variance for head applications.
DCE phantom longitudinal analysis resulted in reproducible R1 estimates at 1.5T and 3.0T with
maximum coefficients of variation 3.0% and 9.4%, respectively. Results of the pharmacokinetic
simulations suggest that the equipment contributed bias and variance is negligible for these levels of R1.
To this point, Hawighorst et al. [70] found significant changes in kep (Ktrans/ve) on the order of 50-142%
compared with pre-treatment measurements, which is comparable with the results of Hayes et al. [84].
Reviews of work investigating DCE-MRI as a means of assessing antiangiogenic and vascular disruption
treatments by Jackson et al. [71] and O’Connor et al. [72] suggest treatment effect changes of 40% or
greater. These results, in combination with the work in this aim, suggest that treatment changes are
easily distinguishable from equipment variance for the equipment monitored in this study. Even
including additional error for setup, as the volume analyses might suggest a level of at most 15%, the
expected treatment changes still exceed these deviations.
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Longitudinal analysis of the diffusion data showed that equipment variances for the ADC estimates
were well below thresholds of change that have been observed in previous work. For example the
University of Michigan group [36] uses a threshold of approximately 30% change in the ADC while
others, such as Mardor et al. [33], have noted changes on the order of 30-70% in responding tissues. A
recent validation of the functional diffusion map [36] by Ellingson et al. [22] found minimum thresholds
of change required, based on significant changes in cellularity, for the ADC values of normal appearing
white matter (0.25x10-3 mm2/s) and gray matter (0.31 x10-3 mm2/s). These thresholds are smaller by a
factor of approximately two compared to those employed in the analysis by Hamstra et al. [36]. Even for
changes of this magnitude (~15%), the equipment variance is still smaller by a factor of approximately
three. The substantial deviations in ADC values as a function of position from isocenter, particularly at
the edges of the volume, reinforce the necessity of reproducible patient setup. Moreover, the drastic
differences observed between field strengths strongly encourage the use of a single field strength when
acquiring longitudinal data. Recent work by Malyarenko et al. [172] suggested that evaluation and
correction of the gradient non-linearities can reduce bias in ADC estimates. However, for the purposes
of this work, not only were images acquired at 1.5T for which the bias in DTI ADC estimates was within
5% across the field of view, but patient setup consistently placed the tumor within approximately 10
mm of the slice at isocenter, suggesting that the treatment-induced changes will far exceed the
deviations in ADC estimates.
This study has provided, over an extended period of time, characterization of bias and variance
associated with quantitative imaging biomarkers for diffusion and DCE applications, elucidating several
areas where bias can be and is introduced as a result of acquisition and/or analysis techniques.
However, several limitations of this work exist, specifically assessment of bias and assessment of
machine variance with regard to DSC exams. Future studies (addressed in detail in Chapter 6), should
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involve careful characterization of temperature and chemical concentration dependencies, allowing a
more thorough assessment of bias and acquisition.
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Chapter 4 A Unified Framework for Assessing Treatment Response

4.1 Introduction
Quantitative imaging biomarkers offer significant promise as indicators for diagnosing, monitoring,
and assessing tissue response for a plethora of treatment modalities, for which the latter appears to
provide much needed improvements to current techniques such as RECIST [4], [7], [9], [14], [75], [76],
[173]–[175]. One significant obstacle to utilizing quantitative imaging biomarkers is the labor and time
intensive image analysis pipeline, requiring image registration between and within multiple data sets for
each patient, identification and selection of image regions (including VIFs for DCE- and DSC-MRI studies),
extraction of pixel or region information, and incorporation of this information into an appropriate
statistical framework. These tasks are performed on multiple series within an imaging exam and across
multiple imaging exams for a single patient, often including in excess of 10,000 images. While numerous
large scale collaborative efforts have manifested in solutions to the various aforementioned
components, such as the Insight Toolkit [176]–[178] and the Medical Image Processing, Analysis, and
Visualization (MIPAV) [179] application, a unified analysis infrastructure for performing these
computations remains unavailable. Other available software packages such as AFNI [180] or ImageJ
[181], again, incorporate major components of treatment response analysis as plug-ins, including the
DCE quantification utility TOPPCAT [182] or the AFNI image registration utility 3dvolreg, but creating a
platform from these software packages that links the necessary built-in tools into a broad multiparametric analysis tool capable of performing longitudinal analyses is infeasible. Additionally, several
groups have produced in-house software packages to accomplish similar analyses [183]–[185], but rarely
are such efforts made available to researchers outside of those groups. An additional constraint
imposed by available software is the lack of transparency in algorithms, which frequently necessitates a
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plethora of validation steps and, in cases of failed validation, software updates by the developer are
required (a potentially time consuming and sometimes altogether impossible task).
To address this need, the MATLAB® programming environment was used to develop open source
code based on object oriented programming (OOP) principles, resulting in an advanced programming
interface (API) and graphical user interface (GUI) – Quantitative Utility for Assessing TreaTment
RespOnse or QUATTRO for short. This code implements a flexible modeling API (linked to the widely
developed statistical libraries of R [186]) and links the highly developed image registration libraries of
ITK [178] to a corresponding API for performing modeling and image registration, respectively, in a
unified workspace.

4.2 Software Implementation, Validation, and Optimization
MATLAB was chosen as the development environment for the programming and graphical
interfaces because of the need for quick development and linking of the ITK libraries. A special class
within MATLAB, known as the handle class, was used as the basis for the API. Handle classes reference
objects (similar to pointers in C/C++) and allow simple operations, such as setting a property, to be
modified into complex computations, eradicating a substantial portion of the data bookkeeping required
by the user. Properties and methods that control data operations are fully accessible to the user, but the
debugged classes remove nearly all of the programming overhead when designing advanced features
(e.g., image registration, computation of parameter maps, or visualization tools). Moreover, OOP
principles, modeled after the ITK [176] class template design, were used to allow rapid prototyping of
additional tools, such as the registration API, other visualizations, and development of new quantitative
modeling framework. A full list of the necessary design components and corresponding descriptions of
the respective functionality can be found in Table 4-1.
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Classes were developed to represent common data types for quantitative imaging exams, which
include an image representation, ROI (or point) representation, and a common workspace for
interaction of those data. Using these classes a programmatic GUI was developed with tools for ROI- and
voxel-based analysis, visualization of images, map overlays, and histograms, and standard input/output
such as reporting analysis results or writing newly calculated maps as DICOM images. Additionally,
development of an efficient scripting interface was added to assist in performing analysis of large
quantities of data.
Essential to quantitative imaging, in particularly longitudinal quantitation, two other important
analysis components required development: quantitative modeling and image registration. Additional
details of these tools are addressed in detail in the following subsections. Briefly, a modeling class was
needed to provide an engine for performing quantitative analysis with many of the standard models and
additional flexibility for adding user-defined models. Image registration is a necessary component of

Description
qt_image
qt_roi
qt_exam
qt_options

Image storage class, providing functionality for reading/writing images and meta
data, displaying images, and applying image transformations and filters
Region of interest storage class, providing functionality for reading/writing, creating
and displaying, extracting voxels from, and transforming regions
Exams storage class, providing tools for creating interactions between qt_image,
qt_roi, qt_models, qt_options, and qt_reg classes
Options storage class (used only with graphical user interface)

qt_models

Modeling class that performs quantitative modeling with available model and fitting
customization. Subclasses for specific model types (e.g., DCE or VFA) were also
developed
qt_response Modeling class that performs statistical analysis of longitudinal quantitative imaging
data
qt_reg
Image registration class that bridges an ITK-developed executable with MATLAB
Table 4-1. Description of QUATTRO classes. These classes, with the exception of qt_options were
designed to perform as stand-alone command prompt software, meaning that users can utilize those
classes even beyond the scope of the QUATTRO GUI (e.g., in scripts or as an API).
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Figure 4-1. QUATTRO GUI screenshot. This is a view of the QUATTRO GUI, showing the main features
and primary use as an image analysis tool. The common exam workspace can be seen in the
expanded dropdown box at the lower left.

serial imaging, whether from the same series or different days. The image registration needed to link the
highly developed, widely supported, open source ITK registration libraries [177] with MATLAB, providing
substantial flexibility in image registration options, offering support for 3D rigid transformations.

4.2.1

Models and Model Validation

Standard models matched to common quantitative imaging strategies were incorporated into
the QUATTRO modeling API (qt_models), including relaxometry, DCE, DSC, and diffusion models,
manifested as individual qt_models sub-classes (multiflip, multiti, dce, dsc, and dwi, respectively). A
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standard non-linear least squares fitting routine (lsqcurvefit) in MATLAB (MathWorks, Natick, MA) based
on trust-region-reflective method [187], [188] or Levenberg-Marquardt [189], [190] numerical
optimization algorithms was incorporated into the modeling API. Experience showed that both
algorithms produced nearly identical results for relaxometry and diffusion data, but DCE and DSC
applications often required the ability to bound specific parameters, limiting the search space to
physically interpretable results. Therefore, unless stated explicitly, the reader should assume that the
trust-region-reflective method was used for all fitting procedures. An additional feature of the modeling
API is the cleaning procedure in which, after initial parameter estimates are estimated, voxels with
suspect fits are refitted using, as an initial guess, parameter estimates from the surrounding good fits
(defined by R2>0.5, an adjustable parameter). In noisy data sets, this additional processing step
mitigated the occurrence of single voxels or small patches of voxels for which unreasonable parameter
estimates were made. Specific details of individual model implementations and validations are
described in the following subsections, with discussions of the physical model and associated
parameters contained in the respective subsection of Chapter 2.
All model validation was performed using digital reference objects (DRO) – essentially synthetic
image acquisitions – to simulate a typical voxel-by-voxel image analysis setting. Because magnitude MR
images were used in this work, stated SNR values were calculated using

√

4.1

where σnoise is the standard deviation of ROI voxels either in air or in a difference image (i.e., noise
voxels), S0 is the phantom estimated proton density (used for VFA and VTI test objects) or ROI-based
signal estimate (used for DWI, DCE, and DSC test objects), and the numerical factor in the denominator
accounts for the Rician distribution of the noise [105]. For each model type, the standard deviation of
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noise voxels was used to estimate the standard deviation of the Gaussian distribution from which
random numbers were drawn. To synthesize MR signal, two random numbers were generated from the
same distribution and added to each synthetic signal datum in the following way:
)

√(

4.2

In equation 4.2, SN is the noisy MR signal generated from the model signal S and two random numbers
(n1 and n2) drawn from the same Gaussian distribution and the subscript N simply denotes a noisy signal.

4.2.1.1 Relaxometry Models
All implemented relaxometry models fitted for the parameter T1 instead of R1, as might be
suggested by equations 2.19 and 2.22, to provide a better scaled parameter search space; recall,
T1=1/R1. FSPGR data were fitted directly according to equation 2.19, whereas the VTI data processing
required an additional step, i.e., signal intensity polarity restoration, which was performed prior to
performing any modeling.
A simple algorithm was developed to perform the polarity restoration. The minimum signal
intensity and corresponding TI, say SImin and TImin, were found in addition to the signal intensity
corresponding to the next smallest TI value (SImin-1) and the next largest TI value (SImin+1). These three
signal intensity values were used to calculate the equation of secant lines based on for four unique
cases of inverting or retaining the signal polarity: (1) none of the SI values required inversion, (2) only
the SImin-1 point required inversion, (3) the SImin-1 and SImin points needed to be inverted, and (4) all three
points needed inversion. For each of these four cases, the Euclidean distances between the SImin point
and the line were calculated, with the line producing the smallest distance determining the best
estimation of the TInull. For each TI value smaller than TInull, the signal intensities were inverted. Noisy
data occasionally caused algorithm failures, in which case the values were manually inverted. Since VTI
data were only used in estimation of phantom parameters using ROI-based analysis, which are easily
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verified manually, performance quantification of the signal conversion algorithm was not considered in
this work.
To quantify the performance of these relaxometry models, two DROs were created, one for
each acquisition strategy. Each DRO was synthesized using a single S0 and a range of R1 values,
summarized in Table 4-2, distributed in rectangular patches measuring 10 pixels in height and 20 pixels
in width. Unique R1 values were distributed across eight rows and six columns of patches with the first
row containing the first eight values, the second row containing the next 8, and so in order of increasing
R1. An example image of the VTI DRO is shown in Figure 4-2 for visual reference. Parameter values were
chosen to cover the range of R1 values in the DCE phantom in addition to numerous intermediate values.

S0
SNR Range
Model Parameters
VFA 5000 500-6000* R1: 0.5, 0.75, 1, 2, …, 45, 46 s-1
VTI 800 250-2500* R1: 0.5, 0.75, 1, 2, …, 45, 46 s-1
DWI 1300
10-2000
ADC: 0.3, 0.35, …, 2.60, 2.65x10-3mm2/s

DCE

5000

500-3500*

Ktrans:0.05, 0.1, 0.15, 0.25, 0.35 min-1
ve: 0.05, 0.1, 0.15, 0.25, 0.5
vp: 0.01, 0.05, 0.1, 0.15, 0.2
Temporal resolution: 1 and 5s

Simulation Parameters
TR=5ms
θ=180o
TE=85ms
TR=5ms
FA=30o
T10,blood=1440ms
T10,tissue=1000ms
r1=4.9 (s∙mM)-1
HCT=0.45
TE=35ms

α: 1, 1.2, 1.4,…, 2.8
β: 1, 1.2, 1.4,…, 2.8
DSC 1000
5-150
rCBV: 0.002-0.48
Temporal resolution: 1s
Table 4-2. Digital reference objects construction parameters. Parameters used to construct the
DROs used for software performance evaluation. Where possible, values were estimated (as
described in the text) from phantom and/or patient data. The last column, “simulation parameters”,
contains all other necessary model parameters used to perform the simulations. *denotes proton
density estimated SNR (not image SNR). For example, the lowest SNR value used for VFA simulations
corresponds to an FSPGR proton density image SNR of approximately 15.
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The value of S0 was also matched to phantom measurements by fitting the VFA or VTI model and
averaging the proton density estimate over all vials and acquisitions of the respective image sets. From
these DROs, new unique noisy reference objects were generated over a range of SNR values. Image SNR
is a function of acquisition parameters (e.g., a function of inversion time or flip angle) because of the
signal dependence on the respective parameter, while noise is invariant. To circumvent this SNR
dependency, image noise was calculated using the standard deviation of an ROI (approximately 600
voxels) placed in air, while carefully avoiding imaging artifacts, and calculated as the ratio of S0 to this
value. SNR minimum and maximum values were calculated for each image on the central slice of the
VFA and VTI series, and used to determine the synthesized SNR range. Similarly, noise and S0 were
estimated in patient VFA data sets, extending the lower range of SNRs accordingly (see Table 4-2).
Gaussian noise was then added to the simulated images as per the discussion in the introduction of this
section. For each SNR level, parameter maps were generated, and limits of agreement and concordance
correlation coefficients were calculated for the voxel-by-voxel estimated values (see section 3.3.2.2 for a
detailed discussion of these metrics) in addition to bias and variance maps.
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Figure 4-2. Example variable inversion time digital reference images. An example image of the
noiseless (left) and noisy (right) VTI DRO. The patches for most values of R1 can be easily seen with
the top left square being the lowest value of R1 and the bottom right corner the largest value of R1.
To better illustrate the added noise, images simulated from two different TI values are displayed,
hence the seemingly different test objects.

4.2.1.2 Diffusion Model
QUATTRO’s modeling API only includes the IVIM model as DTI2 modeling is currently
available in an efficient, widely used implementation on available GE Advantage Windows workstations
that provide utilities to export the resulting maps as DICOM images, and cross-validated with QUATTRO
parameter estimates from DWI images (section 3.4.1.3). The IVIM model, in the simplest form (equation
2.15), was validated using a DRO with forty-eight unique, evenly spaced ADC values using the same
image dimensions as the VFA and VTI DROs. ADC values were chosen to encompass the range of values
in the ADC phantom and extended to include the self-diffusion coefficient of pure water reported in
literature [93], [191]. For each ADC value, a corresponding T2 value was estimated using a fitted cubic
2

DTI modeling is, in fact, the only component of this work, including that of specific aim 1 and 3, which was
analyzed outside of QUATTRO’s framework.
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polynomial to interpolate the ADC phantom relaxometry data acquired at 4.7T (see Figure 3-8),
effectively reducing the value S0. T2 estimates at 4.7T were chosen over the corresponding 3.0T
estimates because of the more robust acquisition method and the fact that T2 values are relatively
insensitive to field strength. SNR ranges were estimated from the ADC phantom by calculating the
standard deviation an ROI placed in air (approximately 600 voxels) and average of individual vial ROIs,
substituting these values into σnoise and S0 of equation 4.1, respectively. SNR estimated from phantom
measurements was remained above approximately 150, however, the lower range was extended to
include a generally accepted lower bound on image SNR for DTI acquisitions [99]. A unique DRO was
created for each level of noise while all other model parameters were held constant. Simulation
parameters are summarized in Table 4-2. Voxel-by-voxel parameter estimates were used to generate
ADC maps, from which the LOA and CCC values were calculated to assess the performance of this fitting
algorithm.
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4.2.1.3 DCE Model
DROs were created to assess the three-parameter generalized kinetic model (equation 2.29)
using the parameters summarized in Table 4-2. Each DRO contained five unique values of Ktrans, ve, and
vp, resulting in 125 unique combinations of those parameters. The five unique Ktrans values, increasing
from left to right, were distributed in vertical strips of twenty pixels, while unique values of vp were
placed in descending horizontal stripes (fifty pixels in height) starting at the bottom of the phantom.
Values for ve were also placed in descending horizontal stripes. However, the height of these stripes was
on ten pixels and the group of five stripes recurred for each section of vp values. Figure 4-3 illustrates
the distribution of parameters. For each combination of PK parameters, the concentration of Gd was
calculated for these “tissue” uptake curves using the VIF described previously (section 3.3.2.2) using a
temporal resolution of 1 and 5s. To simulate noisy images, the tissue uptake curves, expressed in mM of
Gd generated from the PK parameter combinations, were converted to signal intensity assuming a
perfectly spoiled FSPGR sequence with an S0 of 5000, FA of 30o, and TR of 5ms (i.e., equation 2.19).

Figure 4-3. Actual pharmacokinetic values of the DCE digital reference object. Actual values of Ktrans
(left), ve (middle), and vp (right) used to generate synthetic tissue uptake curves. The DRO is 250
pixels in height and 100 pixels in width.
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Noise was then added as discussed previously to these signal intensity values at each time point. Since
the VIF was generated separately from the rectangular DRO, noise was simulated as described
previously for 50 unique VIF signal intensity curves (all derived from the noiseless VIF) and the average
of these curves was used as the “measured” VIF when estimating PK parameters from the noisy DRO,
simulating averaging over a user-defined VIF ROI. As with the previous models, noise levels were
estimated from patient and phantom data, image SNR in this case. For phantom data, subtraction
images were created between the subsequent images in the serial DCE acquisition and ROIs for each of
the sixteen vials were used to compute the SNR from the subtraction images using equation 4.1. Noise
estimation from patient data utilized this same procedure for pre-contrast images in the DCE series,
extracting noise from the physician-defined tumor ROIs (i.e., tumor contours). S0 was not estimated for
these data, but rather assumed arbitrarily to be 5,000 (noise was scaled appropriately). Once maps were
generated from each of these synthetic data sets, LOA and CCC values were calculated to assess the
algorithm performance.

4.2.1.4 DSC Model
Modeling of the rCBV relies on estimation of a gamma-variate fit (equation 2.45) for each
voxel, since only the first-pass of the CA bolus was considered in this work. To determine the range of
simulated fit parameters, estimates of the VIF ΔR2* integral and tissue rCBV (equation 2.44) values were
generated from the patient data sets. The ΔR2* integral (~340), averaged over all VIFs and patients, was
approximated well by a gamma-variate with shape parameters of α=2.85 and β=3; the scaling constant κ
was set to 1. Various combinations of shape parameters were mapped to find those values of α and β
that satisfied the patient-estimated rCBV value ranges, as summarized in Table 4-2. Similarly to the DCE
DRO, all nineteen unique α values were distributed in vertical stripes with a ten pixel width and unique β
values were distributed in horizontal stripes ten pixels in height, resulting in a DRO of 190-by-190 pixels.
Image SNR values were computed from patient data sets as described in previous section (4.2.1.3) using
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a large ROI placed in the centrum semiovale of the frontal lobe. An arbitrarily chosen value of S0 was
used (though the value was close to the patient-averaged VIF S0, 876), scaling the noise appropriately.
Using this set of parameters, arbitrary [Gd], derived from the gamma-variate fit, was generated and
converted to signal intensity curves by the inverse of equation 2.50on a patch-by-patch basis. Noise was
then added to these simulated tissue signal intensity curves to create unique DROs each with a different
level of noise, where the VIF simulation approach of the previous section was used, averaged over ten
simulated time courses (similar to in vivo VIF ROI sizes). Voxel-by-voxel gamma-variate fitting and rCBV
estimation was then performed, and LOA and CCC values were calculated to assess the algorithm
performance.

4.2.2

Image Registration and Registration Validation

Routines for performing image registration were developed from the ITK libraries (version 4.3.2)
and linked to the qt_reg API through an executable. 3D rigid image registration was performed using
Mattes mutual information [192] as the similarity metric and an implementation of a regular step
gradient descent optimizer [193]. In addition to Mattes mutual information, the more common ViolaWells implementation of mutual information [194] and normalized correlation [195] were incorporated,
but were otherwise unused in this work. In addition, other basic registration options such as the
smallest/largest gradient step size, initial transformation guess, number of image pyramid levels,
minimum signal intensity, and number of spatial samples to use in computation of the similarity metric
were incorporated into the interface, which allowed fine-tuning of the algorithm’s performance.
One of the major advantages of using ITK, although there are many, is the extensive validation
and continued development, which provides the expansive user base the most up-to-date image
analysis technologies [178], [196]. Therefore, the need for exhaustive validation of the individual
software components is unnecessary, leaving only the need to select appropriate registration settings to
optimize the task specific accuracy of the implemented algorithms. To accomplish this, 100 randomly
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generated transformations were applied to a digital phantom matching the imaging volumes of the data
analyzed in chapter 5 (see Table 5-1) as closely as possible based on a digital FSPGR simulation of the
human head from the Montreal Neurological Institute [197]. Specifically, twelve slices with a thickness
of 5mm were used with a FOV of 20cm. Image registration was then performed using the same
generated transformations for several combinations of settings where the emphasis was placed on
registration accuracy and not speed, although the latter was quantified. Once registered, displacement
vectors were computed for each voxel within the non-zero voxels of the head and the average, median,
and displacement ranges were computed for this vector field. Exclusion of zero-valued voxels avoided
biasing the error estimate with voxels that would not be considered in the image analysis. These
seemingly larger displacements occur as the result of being far from the center of rotation, not
necessarily from misregistration. Finally, the set of registration options that offered the most accurate
results were used to register an additional 10,000 random transformations to better estimate the
accuracy of the algorithm for the synthetic data.

4.2.3

Code Optimization

Quantitative imaging produces immense data sets, the analyses of which can, in some cases,
require several hundred to thousands of hours of total CPU time. Although the processing of these data
is generally not time sensitive, substantial improvements can be easily gained through utilization of now
ubiquitous multiple core processors. MathWorks offers, within the Parallel Computing Toolbox, tools for
the distribution of computations across multicore processors, graphics processing units, and computer
clusters. In particular, the computation of parameter maps had substantial potential for improvements
in computational efficiency by distributing the workload, resulting in the development of parallel
computation infrastructure. To evaluate the performance improvements, parameter maps for a single
DCE image were computed using between one and four cores. Note that ITK utilizes multi-threaded
computations whenever applicable. In addition to parallelization, special computationally efficient
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functions were implemented for use with curve-fitting routines and other processing pipelines within
the various APIs.

4.3 Results
4.3.1

Relaxometry Validation

R1 maps were generated for the synthesized VFA and VTI digital phantoms for all levels of SNR. BlandAltman plots calculated from all voxels of the resulting parameter maps, shown in Figure 4-4, clearly
illustrate the dependence of bias and variance associated with noisy parameter estimations as a
function of SNR. Because these values were computed from every voxel, encompassing the entire range
of R1 values, the results are not illustrative of the relationship between the bias/variance and R1. To
investigate this relationship, maps of percentage error were computed (see Figure 4-5) by averaging the
percent error over each R1 patch, equivalent to averaging over a 100 voxel ROI. Bias was relatively small,
even for the highest noise levels, not exceeding, in magnitude, 2.9% or 2.1% error for the VFA or VTI
simulations, respectively. Comparing Figure 4-4 and Figure 4-5 elucidates the cause of bias in the low
SNR regime of the VTI model. Essentially, the large, positively biased R1 estimates outweigh the
computation of the average bias, when taken across all DRO pixels. Similarly, variance investigations
were performed to explore the R1 dependence by computing maps of the COV of relaxation rate
differences for each R1 patch at all SNR levels, showing (Figure 4-6), as expected, increasing variance
with decreasing SNR. The COVs for VFA estimation were roughly 0.75% on average, reaching a maximum
of 12.6%. For the VTI simulations, the average COV was 0.29% and maximum COVs of 3.0% were seen.
Finally, the CCC was greater than 0.998 for both DROs evaluated at all noise levels, suggesting excellent
agreement between the actual and estimated parameters.

93

Figure 4-4. R1 Bland-Altman plots for the VFA and VTI digital phantoms. Summary plots of the
Bland-Altman analysis performed (averaged over all DRO voxels) for the VFA (left) and VTI (right) test
objects. The red “x” symbols, which appear as a solid line because of the high density, denote the
DRO averaged bias, where the black lines above and below these symbols represent the limits of
agreement. For comparison visual comparisons, a line of zero bias was also plotted.

Figure 4-5. R1 percent error maps for the VFA and VTI digital phantoms. Percent error from the true
value as a function of SNR and R1 averaged over all voxels of each respective relaxation rate for VFA
(left) and VTI (right) simulations. The color bar shows the percent difference from the actual
parameter used to simulate the MR signal.
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Both DROs exhibited similar trends in the bias and variance associated with fitting noisy data.
Namely, decreases in SNR were associated with increases in the level of bias and variance. This trend
was especially pronounced at higher R1 values in the VTI DRO and low R1 in the VFA DRO, illustrating the
parameter space region where the respective acquisition method becomes most sensitive to noise. This
sensitivity, for VFA acquisitions, is the result of substantially reduced signal (a byproduct of the short TR)
for low relaxation rates, resulting in noise dominated signal. VTI acquisitions exhibit increased bias for
high relaxation rates as a result of the rapid signal recovery from –S0. In practice, lower bounds often
exist on the values of TI (50ms for the scanners used in this study), resulting in inadequate sampling of
the dependence of the signal intensity on TI. In this study, for R1 values greater than approximately 14s1

, the signal remains above the null point, yielding a poor data representation of the physical model

(equation 2.22).

Figure 4-6. R1 difference coefficient of variation maps for VFA and VTI digital phantoms. Maps
showing the coefficient of variation of R1 bias for VFA (left) and VTI (right) simulations averaged over
all voxels for a given R1 value. The color bar shows the COV in %. COV was chosen over other
measures of spread because of the normalization, allowing quick comparison of different parameter
values.
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Figure 4-7. ADC Bland-Altman plot for the diffusion digital reference object. Summary plot of the
Bland-Altman analysis performed (averaged over all DRO voxels) on the ADC test objects are shown.
The red “x” symbols, which appear as a solid line because of the high density, denote the DRO
averaged bias, where the black lines above and below these symbols represent the limits of
agreement. For comparison visual comparisons, a line of zero bias was also plotted, although this
line is not readily visible.

4.3.2

Diffusion Validation

ADC maps were generated for the simulated DWI acquisition for the range of SNR values listed
in Table 4-2. Figure 4-7 illustrates the SNR dependence of bias/variance (Bland-Altman plot) for
differences between the estimated and true ADC values averaged all DRO voxels at each SNR level.
These results suggest excellent agreement between ADC estimates and the true values, corroborated by
a CCC of greater than 0.88 for all SNR levels (1.00 for SNR levels found in phantom data). To illustrate the
parameter value dependence of bias and variance, maps for the percentage error and COV were
computed and are shown in Figure 4-8. A maximum absolute bias of 13.0% was found when considering
all SNR levels, limiting these levels to those measured in the phantom yielded a maximum bias of 0.87%.
The COVs, on average, were approximately 0.55%, reaching a maximum of 29%. Again, when
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considering only those SNR levels measured in the ADC phantom, the average and maximum COVs were
0.33% and 5.26%, respectively. Bias and variance results for the diffusion model suggest minimal
influence of the model fitting routine, even when considering SNR levels substantially (by an order of
magnitude) below that of a standard acquisition.

Figure 4-8. ADC percentage bias and coefficient of variation maps for the diffusion DRO. Percentage
error (left) and coefficient of variation (right) maps for ADC as a function of SNR. The color bars show
the percent error (left) and the percent COV (right).
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Figure 4-9. Bland-Altman plots of PK parameters as a function of SNR. Summary plots of the BlandAltman analysis performed (averaged over all DRO voxels) on the DCE test objects are shown. The
red “x” symbols denote the DRO averaged bias, where the black lines above and below these
symbols represent the limits of agreement. For comparison visual comparisons, a solid black line of
zero bias was also plotted.
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4.3.3

DCE Validation

Ktrans, ve, and vp maps were generated for the simulated DCE acquisition using the range of SNR
values listed in Table 4-2. Figure 4-9 illustrates the Bland-Altman analysis as a function of SNR for
parameters estimated from one and five second temporal resolutions. Consistent underestimate of Ktrans
and ve are seen at both temporal resolutions on average, with substantial differences in the variance
between the two resolutions (increasing with temporal resolution). The vp results exhibited the same
trend in variance, though notable differences were seen in the bias. Namely, vp was consistently overestimated with increasing temporal resolution. These results are consistent with the observation of
increasing bias with temporal resolution of Aerts et al. [164] and Cao et al. [165]. Again, these results
indicate, on the whole, performance of the algorithm averaged over all parameter values, neglecting the
influence of SNR, temporal resolution, and the actual parameter values. Similarly to the relaxometry and
diffusion model analysis, maps of bias and COV were generated as a function of SNR and model
parameters. Additional model parameters (more than 2) inhibit straightforward visualization of these
metrics as a function of model parameters and SNR, resulting in five unique Ktrans percent difference 3D
scatter plots, one for each value of vp, at the high sampling rate (Figure 4-10), and five Ktrans percent
difference plots for the lower temporal resolution (Figure 4-11). Comparison of these bias figures
confirms the general trend of increasing parameter estimates as temporal resolution decreases, and for
all parameters, increasing bias with decreasing SNR. In addition to the trend of deceasing Ktrans bias with
increasing vp, another trend of decreasing Ktrans bias with decreasing ve is clearly visible at both temporal
resolutions, particularly for higher values of vp. Ktrans bias exhibited a slight increasing trend with
decreasing Ktrans, although slightly less apparent at the higher temporal resolution. Overall, the
maximum absolute Ktrans bias was 10.4% and 13.9% and averaged absolute bias was 1.4% and 1.8% for
the 1s and 5s temporal resolutions, respectively. Absolute maximum and average percent errors for ve
were similar to those of Ktrans, 23.1% and 1.1%, respectively, at the high temporal sampling rate and for
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those at the lower sampling rate, 23.2% and 1.1 %, respectively. The ve percent bias plots are shown in
Figure 4-13, and increased bias can be easily seen at the edges of the parameter space (i.e., low/high ve,
vp, and Ktrans). However, vp exhibited substantially higher bias (Figure 4-12) in magnitude and on average
at the lower sampling rate, 100% and 17.8%, respectively, while the values at the 1s resolution, 3.7%
and 29.0%, respectively, were comparable with other PK parameters.
Parameter variance was minimal for Ktrans with COVs less than 4% in magnitude and on average
less than 0.75% at both temporal resolutions. The ve results varied substantially more in magnitude at
the lower sampling rate (9.6% max COV), but, on average, COVs were less than 1%. However, variance in
the estimate of vascular plasma volume was substantially more. The COVs for the 1s sampling interval
were found to be less than 1%, on average, and nearly 10% in magnitude, with those values for the 5s
interval reaching 27% and greater than 1400%. Most of this additional variance, not surprisingly, can be
attributed to the lowest value of vp, as removal of these data yields COVs of approximately 0.6% on
average and 5.9% in magnitude for the lower temporal resolution. These results clearly indicate the
need for careful assessment of parameter estimates, particularly in regions of low vp.
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Figure 4-10. DCE DRO percent bias maps for estimated Ktrans at 1s temporal resolution. Color maps
of the percent bias as a function of the actual value of vp (0.05-top left, 0.1-top right, 0.15-middle left,
0.2-middle right), ve on the y-axis, Ktrans on the x-axis, and SNR on z-axis. The color bar represents the
percentage difference between the estimated parameter and the actual parameter value.
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Figure 4-11. DCE DRO percent bias maps for estimated Ktrans at 5s temporal resolution. Color maps
of the percent bias as a function of increasing vp (0.05-top left, 0.1-top right, 0.15-middle left, and
0.2-middle right), ve on the y-axis, Ktrans on the x-axis, and SNR on z-axis. The color bar represents the
percentage difference between the estimated parameter and the actual parameter value.
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Figure 4-12. DCE DRO percent bias maps for estimated vp at 5s temporal resolution. Color maps of
the percent bias as a function of increasing vp (0.51-top left, 0.1-top right, 0.15-middle left, and 0.2middle right), ve on the y-axis, Ktrans on the x-axis, and SNR on z-axis. The color bar represents the
percentage difference between the estimated parameter and the actual parameter value.
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Figure 4-13. DCE DRO percent bias maps for estimated ve at 5s temporal resolution. Color maps of
the percent bias as a function of increasing vp (0.05-top left, 0.1-top right, 0.15-middle left, and 0.2middle right), ve on the x-axis, Ktrans on the y-axis, and SNR on z-axis. The color bar represents the
percentage difference between the estimated parameter and the actual parameter value.

4.3.4

DSC Validation

rCBV maps were generated for the simulated DSC acquisition for each SNR level used to
simulate the MR acquisition, as listed in Table 4-2. Results of a Bland-Altman analysis and CCC
computations for all voxels as a function of SNR are summarized in Figure 4-14. These results suggest, as
expected, increased bias and variance as the noise levels increase (i.e., SNR decreases), albeit slight
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trends. The CCC results as a function of SNR suggests a drastic departure in the estimated values from
the true values. However, this trend is likely the result of a small number of highly biased rCBV values.
To further investigate the cause, the SNR dependence of bias, specifically percent bias, was mapped and
is shown in Figure 4-15, in addition to a map of the COV. A maximum absolute bias of approximately
1000% was found, however, comparison with the bias map suggests that these large deviations from the
true rCBV occur at very low SNR/rCBV values and are few in number. In fact, more than 80% of the
SNR/rCBV combinations shown in Figure 4-15 are within 5% of the true rCBV. Similarly, the average and
maximum COV values were meaninglessly large (greater than 1000%). This again occurs in an isolated
region of the parameter space and is most likely the result of small variations in values close to zero.

Figure 4-14. rCBV Bland-Altman plot and CCC plot as a function of SNR for the DSC DRO. Summary
plots of the Bland-Altman analysis performed (averaged over all DRO voxels) on the DSC test objects
are shown. The red “x” denotes the DRO averaged bias, where the black lines above and below these
symbols represent the limits of agreement. For comparison visual comparisons, a solid black line of
zero bias was also plotted.
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Figure 4-15. rCBV percentage bias and COV maps for the DSC DRO. Percentage error (left) and
coefficients of variation (right) maps for rCBV as a function of SNR. The color bars show the percent
error (left) and the percent COV (right).

4.3.5

Image Registration

Numerous combinations of the minimum signal intensity, minimum gradient step size, and
number of pyramid levels were tested using the same 100 randomly generated transformations. For the
expected magnitude of transformations required in this work, a single level (the original image
resolution) was found to provide the most accurate results when signal intensities greater than or equal
to zero were used. No additional improvements in accuracy were found by decreasing the minimum
step size below a value of 1x10-4. This set of registration settings provided sub-voxel accuracy when
registering noiseless simulated FSPGR images, and was used in all subsequent work. Using the finetuned settings, 10,000 random transformations were applied to the same image set and the images
were re-registered. The average voxel displacement from the original position, averaged over all random
transformations, was approximately 0.73mm with a standard deviation of 0.074mm. These results
suggest excellent rigid alignment accuracy.
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4.3.6

Code Optimization

Parallel computations were implemented for parameter map calculations. The computations
were benchmarked using a single 250x100 voxel DCE image data set. Total computation time for a single
processor was measured at 866s (approximately 14min). Using two and four processors resulted in
improvements (reductions in processing time) of 16% and 27%, respectively. Much of the computation
time contributing to this relatively small gain in computational efficiency was the result of the parameter
re-estimation algorithm, which accounted for 633s of the total computation time stated for a single
processor. Removing this value from the total processing time resulted in gains of 203% and 484% for
two and four cores, respectively, results comparable to the expected improvements in processing time.
Unfortunately, the post-processing re-estimation algorithm depends on neighboring parameter
estimates during each iteration, rendering multi-threaded processing incompatible with the task.

4.4 Discussion
Quantitative analysis of multi-parametric MR imaging data is a multifaceted, time-intensive
process requiring a plethora of tools for quantitation and meaningful representation of imaging
information. These tools, along with the equipment used to acquire data, require rigorous assessment
to ensure that bias and variance are quantified, and, where possible, mitigated in an effort to avoid
propagating unnecessary errors through the image analysis and, ultimately, the response assessment
framework. This study aimed to develop the tools necessary for providing a unified environment, in
addition to assessing/mitigating bias and variance through the use of synthesized digital reference
objects representing values commonly measured in vivo and analyzed in the same manner as patient
data sets.
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QUATTRO was developed in the MATLAB environment using object oriented programming
principles, linking other commonly used and highly developed programmatic tools, specifically ITK and R.
The flexibility afforded by MATLAB allows further customization and development of tools associated
and/or derived from any of the developed classes summarized in Table 4-1, in addition to providing a
unified workspace for performing analysis of quantitative images. While these basic tools provide a
relatively comprehensive image analysis framework, the linkage of QUATTRO with the libraries of ITK
and R provides innumerable possibilities for more advanced image registration procedures (e.g.,
deformable image registration) and statistical analysis, respectively. Parallelization tools were also
incorporated to improve performance of parametric map computations using a framework that can be
extended easily to incorporate other amenable computational tasks. Although these tools were
benchmarked using a single multi-core CPU, the increasing availability of machines supporting GPU
computations and high performance computing clusters (e.g., cloud computing) affords opportunities
for further expansions of parallelization capabilities.
Each of the pre-programmed modeling modes and the image registration algorithm was
validated using QUATTRO’s tools to quantify inherent bias and variance of the algorithms’ performance.
Model validation showed no substantial bias and variance introduced for the relaxometry and diffusion
models. For temporal resolutions comparable to clinical acquisition schema, DCE validation results
suggested increased bias, when compared with faster sampling rates (e.g., 1 frame/s). In addition to
increased bias, substantial variance was observed in the lower range of tested vp (<0.02). All other PK
parameters were relatively robust with respect to bias and variance. Similarly, validation of the gammavariate fitting for DSC models resulted in substantially increased bias and variance for small values of
rCBV (<0.02 and <0.05, respectively).
QUATTRO was the manifestation of considerable efforts focused on developing a unified
workspace for performing quantitative image analysis in the context of treatment response, the goal of
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this specific aim. The performance of the various built-in models was validated and characterized using
simulated data sets. Future work should involve development and incorporation of advanced modeling
and image registration techniques (see Chapter 6 for additional details).
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Chapter 5 Radiological Response Maps

5.1 Introduction
Evaluation of novel targeted or combined therapeutics using traditional measures of response,
such as RECIST [1] and RANO [2], has faced a number of challenges. Increasingly, functional MR QIBs,
many of which are potentially suitable for use as surrogate endpoints, are being incorporated into
clinical trials, as evidence supporting the ability of these markers to assess treatment response is
growing [7]–[18]. Myriad studies have demonstrated correlations between QIBs and histological
samples [20]–[32], [37], [43], [56], [62]–[64], and, moreover have established a relationship between
patterns of QIB changes and treatment response [18], [33]–[39], [70]–[72]. As increasingly complex
therapies are performed, establishing methods for elucidating locoregional tissue response offers
promise as a means of assessing the heterogeneity associated with treatment induced changes.
In an effort to capture these biological changes associated with treatment, a multi-parametric
statistical framework was developed that provided a means of producing voxel-by-voxel predictions of
treatment response. A small cohort of patients having undergone advanced imaging studies was
retrospectively evaluated, including acquisition of DTI, DCE, and DSC imaging data sets, in an effort to
preliminarily identify an appropriate model and evaluate the generalizability of that model.

5.2 Patient Acquisitions
Retrospective analysis was performed on a cohort of patients (n=13) with surgically resected
recurrent glioblastomas. All 13 patients received concurrent radiation therapy and temozolomide plus
or minus bevacizumab. Of these 13 patients, 6 were treated without bevacizumab, 6 were treated with
bevacizumab, and the treatment status, with regard to bevacizumab, 1 patient is unconfirmed. This last
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patient, in the professional opinion of our expert radiation oncologists, is thought to have been treated
without bevacizumab. Patients underwent advanced MRI imaging four times during this study. The first
study was performed approximately one week prior to chemoradiation (and/or bevacizumab) therapy (4
weeks post-surgery), two studies were performed 3-4 weeks mid-treatment, and one post-treatment
study was performed 3-5 weeks after treatment was complete. Pre-treatment scans, which occurred
5.6±0.8 (mean ± SEM) days pre-treatment (24.6±1.8 days post-surgery), and both mid-treatment scans,
occurring at 21.5±0.3 days and 24.8±1.1 days after treatment was initiated. Table 5-1 summarizes the
quantitative acquisition protocol.

5.3 Methods and Materials
All work described in the following sections was performed using QUATTRO. A combination of
DCE
DSC
DTI
Coil:
8CH Brain
8CH Brain
8CH Brain
Sequence:
3D FSPGR
GRE-EPI
SE-EPI
User CVs:
Turbo=2
--ASSET=2
TE (ms):
1.3
35
91.8
TR (ms):
6.4
1500
10000
BW (kHz):
+/-62.5
+/-250
+/-250
NEX:
1
1
1
Flip Angle (deg.):
30
90
90
b-value (s/mm2):
----0, 1200
FOV (cm):
24
24
24
Phase FOV (%):
0.75
1
1
Sl. Th. (mm):
5
5
5
Gap Th. (mm):
----1
Num. of Slices:
12
12
25
Num. of Frames:
56
120
27*
Matrix:
256x160
128x128
128x128
Table 5-1. Patient DCE, DSC, and DTI phantom protocol acquisition parameters. The temporal
resolution of the DCE scan was approximately 6.3s. *Denotes the number of diffusion encoding
directions (one b0 image was acquired). Abbreviations: Num. = Number, Sl. = Slice, Th. = Thickness
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GUI and command prompt functionality was used in addition to numerous QUATTRO and MATLAB
scripts. The only portion of the following analyses to be performed outside of QUATTRO was the
computation of the DTI quantities (ADC and FA). Images were transferred and analyzed on the Linux
workstation described in section 3.3.2.

5.3.1

Image Registrations

Rigid image registrations executed with the qt_reg class were used to align all imaging volumes.
As discussed in section 4.2.2, the image registration parameters were fine-tuned for the DCE, DSC, and
DTI data sets. Briefly, a single pyramid level (native image resolution), tri-linear interpolation, and a
minimum step size of 1x10-4 were used to perform all alignments. In circumstances where the voxel sizes
between the template and moving imaging volumes were disparate, the larger voxel size was resampled
to match the higher resolution volume. Intra-series (same day serial acquisitions), inter-series (same
day, different series), and longitudinal (different dates, same series) were performed independently.
Intra-series alignment was performed for DCE, DSC, and DTI data sets prior to generating any
parametric maps. For a given serial DCE acquisition, all serial images were registered to the first frame in
the series. A similar methodology was used for the DSC series, but the third frame in the series was used
in lieu of the first frame to avoid non-steady state signal intensities. All non-zero b-value images in the
DTI series were registered to the b0 image. Following estimating of the image registration
transformations, voxel displacements averaged across the volume were calculated and transformations
were only applied to images for which the average displacement was greater than the minimum voxel
dimension. Intra-series registrations were only used to adjust for slight patient motion during the serial
acquisitions prior to performing acquisition appropriate quantitative analysis; these transformations
were otherwise unused.
Voxel-by-voxel analysis of radiographic response required co-registration of all parametric maps
for a given patient, a two part procedure. For a given patient and imaging study date, any inter-series
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patient motion was corrected for by aligning the DSC and DTI imaging volumes to that of the DCE series.
Although the DCE and DSC volumes were identical, the acquired imaging matrices were different by a
factor of four, which was corrected by first resampling the DSC images to 256x256 (original matrix:
128x128) prior to aligning the volumes. As with the series registrations, the first DCE series was chosen
as the template volume and the third frame of the DSC time series selected as the moving volume.
Differences between the DCE and DTI volume extent and slice spacing, required additional
considerations. Prior to co-registering the DCE and DTI data sets, DTI slice spacing was resampled to that
of the DCE image set (i.e. 5mm thickness and no gaps) and the DCE image volumes was padded with
zeroes so as to be commensurate with the diffusion image volumes. Following alignment of the b0 DTI
volume to the first DCE series volume, the DTI imaging volume extending beyond that of the DCE
volume was removed, resulting in equivalent voxel dimensions and volume extent. All volume
transformations were stored as ITK iteration files, a qt_reg specific text-based file format storing
algorithm setup details, the transformation and similarity value at each iteration, and the algorithm stop
criteria. Similarly, longitudinal imaging data were co-registered. DCE, DSC, and DTI longitudinal volumes
were registered to the corresponding volume of the pre-treatment date using the native resolution. As
described previously, the first series volume of the DCE acquisitions, the third serial DSC imaging
volume, and the b0 image of the DTI data sets were used for co-registration, and all resulting
transformations were stored as ITK iteration files.
Image transformations were calculated and stored, but the application of those transformations
was performed simultaneously to avoid introducing image interpolation artifacts. The qt_reg class
provides a method for generating a single transformation from serial rigid transformations. To generate
the new imaging volumes used for radiographic assessment and subsequently extraction values from all
parametric maps, the inter-series transformations were imported from the ITK iteration files into qt_reg
followed by the longitudinal transformations. A single transformation matrix was automatically
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calculated and applied to each of the DCE, DSC, and DTI imaging volumes and parametric maps. By
generating the registered volumes in this way, as opposed to creating intermediate transformed imaging
volumes, propagation of interpolation artifacts was avoided. These transformed images were used for
visual assessment of registration success and the images of the transformed DCE series provided a
volume on which the oncologist drew all response ROIs.

5.3.2

Quantitative Image Analysis

As discussed in section 2.1.3, DCE modeling was performed using the three parameter general
kinetic model (equation 2.29) on a voxel-by-voxel basis. VIFs were manually defined on a central slice of
the imaging volume using a polygon ROI by an iterative selection process. All three longitudinal DCE
exams were visualized simultaneously. Candidate blood vessels were delineated and the time courses
for the manually defined VIFs of each study date were compared qualitatively. Blood vessels for which
in-flow enhancement was minimal and for which qualitative features such as peak enhancement, bolus
shape, and washout were most similar were used to define the VIF for that respective DCE study. During
the VIF selection process, the number of pre-contrast images was determined by visually inspecting the
baseline signal, identifying the last time point before substantial trending increases in signal intensity
were observed which denoted the number of baseline images. After defining the VIFs and determining
the number of pre-contrast imaging phases, the DCE settings of QUATTRO were updated and parametric
maps for Ktrans, ve, vp, and R2 were calculated using the change in signal intensity (equation 2.41) and the
intra-series registered images as discussed in section 5.3.1, noting the discrimination criteria for
application of the image transformations. DCE modeling performed in QUATTRO averages the signal
intensity of all pre-contrast images before calculating the change in signal intensity with no additional
image processing.
DSC data were analyzed in a similar fashion to the DCE data. Since only first pass kinetics were
considered, a manually defined recirculation cut-off was determined during the VIF selection process in
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addition to the number of pre-contrast images. Determination of the number of pre-contrast images
was identical to that of the DCE analysis and the recirculation cut-off was chosen to be the frame after
the peak [Gd] concentration in the VIF time course for which a visually perceptible change in the
negative slope was present. Figure 5-1 illustrates two examples of pre-enhancement and recirculation
cut-off selections. QUATTRO settings for the DSC exam were updated with these parameters, and
computation of a voxel-by-voxel gamma-variate fit was performed. Prior to fitting each voxel CA time
course, a gamma-variate is fit to the VIF and the estimated bolus arrival time (BAT) is used, in
conjunction with the recirculation cut-off, to provide bounds for the individual voxel BAT estimation. In
practice, this was found to prevent, at least in part, a vast majority of gamma-variate fits with
unreasonably large integrals (on the order of 108). Following these initial processing steps, gammavariate parameter maps and corresponding R2 maps were computed. A Gaussian-Kronrod method,
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implemented in the MATLAB function quadgk [198], was used to numerically integrate the individual
voxel gamma-variate and the VIF fits, taking the ratio of the two integrals yielding the rCBV map. Again,
the intra-series DSC registrations were used where appropriate.
DTI data sets, following application of intra-series registration, were transferred to a GE
Advantage Windows Workstation running FuncTool (GE Healthcare, Waukesha, WI, version 4.5) using
FTP. Images were initialized in FuncTool and signal thresholds were set to the smallest allowable
minimum and largest allowable maximum values to ensure diffusion parameter computations were
performed in all voxels. ADC and FA maps were computed and stored in DICOM format, after which the
data sets were transferred back to the Linux workstation for further analysis. QUATTRO scripts were
developed to import the ADC and FA maps into the corresponding DTI QUATTRO save files.

Figure 5-1. Example pre-contrast and recirculation cut-offs for DSC VIF. Two examples of a DSC VIF
demonstrating the manually defined pre-enhancement (first dotted vertical line) frames and the
bolus recirculation cut-off (second vertical line). The small squares are the measured data,
converted from signal intensities to arbitrary units of [Gd], and the solid line is the fitted gammavariate. Note that even though the pre-contrast frame is manually defined a value for the bolus
arrival is actually one of the fitting parameters.
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5.3.3

Radiological Assessment

Two experienced radiation oncologists provided consensus radiological assessment of each
patient. Both oncologists were instructed to contour areas surrounding the surgical cavity, using all
clinical data available at the conclusion of the quantitative imaging study, with labels of partial response
(PR), stable disease (SD), and progressive disease (PD). Initial imaging studies were reviewed, tracking
changes throughout subsequent quantitative imaging studies. In addition to imaging information,
consideration was given to the radiation therapy treatment plan to potentially discriminate treatment
effects from progressive disease. All ROIs were drawn on the co-registered (between series and imaging
study dates), during which time the oncologists verified the success of the individual rigid registrations.

5.3.4

Statistical Classification and Response Maps

Ordinal regression was performed on a voxel-by-voxel basis using the individually and consensus
defined radiographic assessments (PR, SD, and PD) as the response variable. Thresholds were defined
for each of the quantitative parameters, except ADC, to prevent modeling physically unrealizable model
parameters, excluding voxels that exceeded those bounds. Bounds on the ADC performed the additional
task of discriminating between tissue and fluid filled cavities remaining from the surgical resection.
Table 5-2 summarizes those physical thresholds. Scripts were created in MATLAB to perform the
longitudinal regression analysis, importing co-registered parameter maps, response ROIs, and extracting
all pertinent data using the qt_exam class. ROIs defined by the radiation oncologists representing the
final patient outcome were loaded through the qt_roi class, and masks were created and applied to all
registered parametric maps, from which voxels were extracted. After applying the parameter
thresholds, resultant voxels extracted in this manner were imported and stored in a qt_response object
as the predictor variable, from which point, generation of visualizations such as histograms and
probability histograms was easily performed.
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A basic model was created to perform initial investigation of subsequent differences (i.e. first
mid-treatment minus baseline and second mid-treatment minus first mid-treatment) of the form
(

)
(

5.1

)

where the subscripts 1 and 2 refer to the baseline/first mid-treatment parameter changes and
differences in the mid-treatment parameters, respectively, and I[…] is an indicator variable defined as,

{

.

5.2

The necessity of this indicator variable arose because the two treatments (placebo and bevacizumab)
were expected to affect different changes in functional QIB, and the incorporation of this additional
term provided a means of specifying a single model for all patients in this cohort. Expansion of the
parenthetical statements included interaction terms between QIBs. Additional models were also
investigated after qualitative analysis of the data was performed, and are discussed in further detail in
the following section (5.4). For each of these covariates (including the treatment indicator), the sample
mean and standard deviation was calculated and used to standardize the covariate, creating covariates
with a mean of zero and standard deviation of one. Regressions were performed as discussed in section

ADC (x10-3mm2/s)

FA

Ktrans (min-1)

ve

vp

rCBV

Minimum
Maximum

0
0
0
0
0
0
1
1
2
1
3
1
Table 5-2. QIB modeling thresholds. Voxels exceeding the thresholds defined in this table were
excluded from the regression analyses, as these thresholds nominally represent physically realizable
parameter quantities of biological tissue.

118

2.2.2 using the ordinal package (version 2013.9-30) developed in R [199], estimating unique regression
coefficients for each model term, including a regression intercept and category cut-offs.
Leave-one-out (LOO) cross-validation, as discussed in section 2.2.3, was incorporated to provide
an exploratory assessment of the generalizability of the developed regression classifiers. When
performing cross-validation with adequate data sets, the data can more easily be partitioned to form
training, validation, and testing data sets. By separating the data in this manner, both components of
cross-validation – model selection and model validation – can be optimally performed. However, the
limited size of the data set in this work was limiting, despite the number of observations (i.e., voxels)
was large. Voxel measurements from the same patient are expected to be highly correlated, requiring
that the cross-validation be performed at the patient level to avoid substantially overestimating the
prediction accuracies. To this end, patients were excluded one at a time, leaving the remaining patient
data sets to train the regression models. For each LOO patient, every combination of the six unique
QIBs, ADC, FA, Ktrans, ve, vp, and rCBV, was fitted to a unique ordinal regression model. For example, one
model might include only the ADC and rCBV parameters, by dropping all other terms from the model
defined in equation 5.1. Of these models, with the accuracies averaged across all LOO cases, the multiparameter model with the highest average accuracy (average of the individual categories’ accuracies)
was compared to the accuracies of the corresponding single parameter models to determine whether
the multi-parameter model was a better predictor of response compared with the single parameter
counterpart.
In addition to the LOO cross-validation, the generalized coefficient of determination was
calculated according to the formulation in section 2.2.2 (equation 2.62) for each model trained during
this process. “Response” maps representing the predicted category on a voxel-by-voxel basis were
generated for individual category probabilities. To avoid confusion in the interpretation of these maps,
each map was masked by the original consensus ROIs.
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Initial results of the ordinal regression (from both qualitative and quantitative analysis)
suggested that the use of three categories (PR, SD, and PD) overextended the capabilities of this
particular data set. Training data from the consensus ROIs exhibited similar behavior, except for the
poor accuracies were present in prediction of the partial response category. As a result, the PR and SD
categories were combined, and a logistic model was also considered with the two categories PR/SD and
PD, similar to the approach taken in the development of the functional diffusion map by Moffat et al.
[34]. Analyses were performed in the same manner as described for the ordinal regression, except there
was no need to estimate category cut-offs since logistic models contain only a single fixed cut-off that is
estimated as the regression intercept. In addition to poor prediction capabilities, initial qualitative
investigations also revealed a non-negligible portion of some ROIs overlapped with the fluid-filled
surgical category. A maximum ADC threshold was determined, as defined in Table 5-2, to provide a
means of rejecting these cavities from the regression model.

5.4 Results
5.4.1

Data Preparation

All image series were successfully co-registered, as verified by the radiation oncologists,
according to the prescription described in section 5.3.1. Inter-series and inter-study image
transformations were applied to a single series of the DCE, DSC, and DTI images sets, in addition to
transforming the respective parametric maps, and were subsequently stored in a separate QUATTRO
ROI save file. The single series images extracted from each of the DCE, DSC, and DTI series were used
only for quick reference when preparing the ordinal regression script. Response ROIs were then drawn
by the two experience radiation oncologists, including the set of consensus ROIs. Finally, calculated
intra-series image transformations were applied to the individual imaging series prior to modeling and
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stored in an appropriate format for modeling (QUATTRO save for DCE and DSC data and DICOM format
for DTI data).
Patient #
1
2
3
4
5
6
7
8
9
10
11

DCE VIF
Superior Sagittal Sinus
Superior Sagittal Sinus
Superior Sagittal Sinus
Superior Sagittal Sinus
Superior Sagittal Sinus
Inferior Sagittal Sinus
Superior Sagittal Sinus
Superior Sagittal Sinus
Inferior Sagittal Sinus
Middle Cerebral Artery
Superior Sagittal Sinus

DSC VIF
Middle Cerebral Artery
Middle Cerebral Artery
Posterior Cerebral Artery*
Middle Cerebral Artery*
Posterior Cerebral Artery*
Middle Cerebral Artery
Posterior Cerebral Artery*
Posterior Cerebral Artery
Internal Carotid Artery
Posterior Cerebral Artery
Middle Cerebral Artery

Table 5-3. DCE and DSC VIF locations. Artery/vein used in defining the vascular input functions used
for quantitation of the DCE and DSC studies.
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Number of Voxels
PR

SD

PD

Totals

-

606
325
2202
148
5336
357

51
2435
352
1695
-

657
325
2435
2202
500
7031
357

-

8974

4533

3
4
9
10

1297
-

1229
21
821

3134
167
1465
569

13507
4363
1464
1486
1390

Bevacizumab

1297

2071

5335

8703

Patient #
1
2
5*
6
7
8
11
Placebo

Table 5-4. Voxel counts for the consensus ROI definitions of both radiation oncologists. This table
summarizes the voxel counts of all ROI data defined in consensus between the oncologists gathered
from all patients and separated by patient, response category, and treatment type. QIB thresholds
were applied prior to calculating these voxel counts. *indicates that the true treatment was
unknown.

VIFs and the corresponding number of pre-enhancement frames were determined for the DCE
studies; the former are summarized in Table 5-3. Following VIF definition, all DCE parameter maps (Ktrans,
ve, and vp) and the associated coefficient of determination map were calculated and transformed using
the inter-series registration results. Resultant QUATTRO workspace data were then saved in a separate
file for ease of access. Results of the DSC analysis, namely VIF locations are also summarized in Table
5-3. VIF gamma-variate fits were verified visually and corresponding R2 values (>0.919, except one VIF
with R2=0.82) were computed and inspected to ensure reasonable VIF fits. Calculated rCBV and R2 maps
were successfully transformed and saved as QUATTRO files, in the same manner as the DCE data.
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Similarly, DTI maps (ADC and FA) were computed successfully on a GE workstation, imported into the
corresponding DTI QUATTRO exam file, transformed, and stored.

5.4.2

Qualitative Inspection

Using the oncologist defined ROI data, voxels were extracted from each of the parametric map,
in addition to tracking the response category and treatment type (placebo or bevacizumab). During this
process, a non-negligible number of R2 values, the criteria used for assessing GKM fits, were found to be
below zero. Further investigation into the source of these erroneous values revealed voxels exhibiting
minimal, if any, enhancement during the course of the DCE acquisition. Nominally, R2 lies in the closed
interval from zero to one, but the use of non-linear fitting in these particular voxels consisting of
primarily noise resulted in the total sum of squares (SStot) falling below one (but greater than zero) and
the residual sum of squares (SSres) attaining a non-negligible value. Since the coefficient of determination
is defined as one minus the ratio of SSres to SStot, the value fell below zero. These voxels were excluded
from further analysis. Resultant voxel counts after applying the parameter and R2 thresholds for these
consensus ROI definitions are summarized in Table 5-4. Immediately obvious from these tabulated data
is the large variation in the number of voxels for each patient and the overall underrepresentation of the
partial response category. In fact, the single collection of PR voxels renders prediction accuracy
assessment using LOO cross-validation impossible, and provides a strong argument for performing
logistic regression by combining the PR/SD into a single category. Another glaringly apparent
characteristic is the large variability in the number of voxels between individual patients. This high
degree of variation and skewedness in the voxel counts is a likely source of bias and variance in the
regression models.
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SD

PD

SD

PD

Figure 5-2. DTI and DSC quantitative imaging biomarker difference histograms for patients
receiving the placebo. Histograms displaying the distributions of QIB differences between baseline
and the first mid-treatment study (left) and between the first and second mid-treatment studies
(right). For a given parameter (label shown under each plot), the x and y limits are held constant,
but vary between parameters.

Difference histograms were also generated based on data grouped by voxel response for the
patients treated with the placebo. DSC and DTI QIB histograms for the placebo group are shown in
Figure 5-2, while the parameter histograms for the DCE analysis are displayed in Figure 5-3. The
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corresponding summary statistics (means and standard deviations) for each histogram were compiled
and are displayed in Table 5-5. Visual inspection of the histograms in Figure 5-2 and Figure 5-3 provides
some potential insight into longitudinal changes in these QIB. For example, between the first and second
mid-treatment imaging studies, the distribution of rCBV in the SD category became skewed towards
decreasing values, suggesting a net decrease in the rCBV, despite the lack of corroboration in the
corresponding summary statistics, which conforms to the expected patterns of tissues response [86].
Similarly, expected response patters are seen in the PD histograms, which in this case are in agreement
with the summary statistics, as FA values appear to increase, consistent with the response pattern of
progressing disease [43]. Despite these reassuring changes, other counter-intuitive trends were also
present. For example, although ADC values initially increased after the initiation of treatment in SD
voxels, a negative overall shift in ADC was observed between the two mid-treatment time points,
suggesting potential cellular proliferation associated with progressive disease. Despite some potentially
interesting visual trends, in general, the large spread of the distributions obscured any large scale trends
in QIB changes, likely resulting from the varying magnitude of responses in the patient population.
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Placebo
Bevacizumab
Placebo
Bevacizumab

ΔADC

ΔFA

ΔKtrans

Δve

Δvp

ΔrCBV

PR

-

-

-

-

-

-

SD

0.15(0.31)

0.003(0.081)

0.027(0.160)

0.023(0.339)

-0.001(0.024)

-0.008(0.22)

PD

0.13(0.33)

-0.018(0.096)

0.009(0.051)

-0.096 (0.42)

-0.002(0.013)

-0.081(0.19)

PR

-0.048(0.20)

0.014(0.079)

-0.006(0.030)

-0.085(0.36)

-0.004(0.014)

0.017(0.15)

SD

-0.008(0.27)

0.017(0.065)

0.014(0.11)

-0.013(0.42)

0.004(0.018)

0.004(0.17)

PD

0.023(0.19)

0.010(0.079)

0.033(0.17)

-0.055(0.40)

-0.002(0.013)

0.001(0.062)

ΔADC

ΔFA

ΔKtrans

Δve

Δvp

ΔrCBV

PR

-

-

-

-

-

-

SD

-0.12(0.25)

0.008(0.062)

-0.014(0.10)

0.043(0.32)

-0.003(0.015)

-0.10(0.20)

PD

-0.11(0.22)

0.038(0.081)

-0.005(0.043)

0.009(0.31)

-0.002(0.011)

-0.051(0.18)

PR 0.001(0.074)

0.007(0.045)

-0.013(0.022)

0.39(0.31)

-0.008(0.006)

-0.12(0.089)

SD

-0.009(0.19)

0.003(0.054)

-0.015(0.11)

0.002(0.31)

-0.003(0.015)

-0.031(0.14)

PD

-0.013(0.13)

-0.008(0.063)

0.017(0.11)

-0.033(0.26)

0.000(0.006)

0.02(0.072)

Table 5-5. Voxel summary statistics grouped by response category and treatment type. This table
shows summary statistics, mean (standard deviation), for differences in QIBs between at the
baseline/first mid-treatment (top) and the second/first mid-treatment (bottom) time points for
voxels from all patients separated by response category and treatment type. All mean values have
physical units corresponding to the parameter of interest.
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SD

PD

SD

PD

Figure 5-3. DCE quantitative imaging biomarker difference histograms for patients receiving the
placebo. Histograms displaying the distributions of QIB differences between baseline and the first
mid-treatment study (left) and between the first and second mid-treatment studies (right). For a
given parameter (label shown under each plot), the x and y limits are held constant, but vary
between parameters.

Surprisingly, the EES parameter, ve, exhibited a large degree of dispersion and an apparent
bimodal distribution for difference histograms created with baseline and the first mid-treatment voxel
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data. Nominally, the fractional EES volume can assume values between zero and one, but little, if any,
physical significance can be attributed to voxels attaining ve values near one. Further investigation into
the collection of voxels values near one revealed, not surprisingly, fitting errors. More specifically, in
noisy voxels with relatively low enhancement, the term describing the plasma fraction (first term of
equation 2.29) is sufficient to explain the majority of the tissue signal enhancement, resulting in an overparameterized, unidentifiable model, arising from the correlation between the two fractional space
terms [200]. These abnormalities are likely the result of poor permeability caused by only partial BBB
disruption. In this regime, Ktrans is usually forced to a relatively small value and ve becomes arbitrarily
large within the parameter bounds [0, 1]. More interesting than the poor fit is the dominance of this
phenomenon in the baseline scan. Although similarly large ve values were found in the two midtreatment scans, the number of voxels found in these later scans was substantially smaller than the
voxel counts of the baseline maps. Approximately 3,300 voxels (of over 22,000) were found to have ve
values greater than 0.9, with only 292 and 579 found in the first and second mid-treatment data sets,
respectively. One possible cause is increased permeability in the BBB resulting from treatment effects.
In addition to creating difference histograms for patients treated with the placebo, an analogous
similar set of histograms was also generated for patients treated with bevacizumab. Selected QIBs
(rCBV, ve, and vp) were chosen to qualitatively illustrate trends as seen in Figure 5-4, though the other
quantities were investigated. As with the previous voxel data, summary statistics can be found in Table
5-5. The rCBV exhibited trends consistent with expected biological change, especially in describing
differences in the first and second difference histogram. Specifically, between the two mid-treatment
studies, the rCBV distribution in PR and SD categories changed from a widely spread set of values to a
more compact, negative mean distribution, while voxels in the PD category exhibited a generally
positive shift, which might be understood intuitively as increasing vascularization. These observations
were corroborated by corresponding changes in vp. For ve, large changes were observed from a well-
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defined collection of values distributed primarily around zero to a widely spread distribution, suggesting
an increase in the EES space associated with positive treatment response. Little change was observed in
the ve values for voxels categorized as SD and PD. Other parameters such as ADC and FA exhibited
qualitative changes similar to those described for the voxels extracted from the QIB maps of patients
treated without bevacizumab.
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PR

SD

PD

PR

SD

PD

Figure 5-4. Selected DCE and DSC quantitative imaging biomarker difference histograms for
patients treated with bevacizumab. Histograms displaying the distributions of QIB differences
between baseline and the first mid-treatment study (left) and between the first and second midtreatment studies (right). For a given parameter (label shown under each plot), the x and y limits are
held constant, but vary between parameters.
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SD

PD

SD

PD

SD

PD

SD

PD

Figure 5-5. Probability histograms for patients receiving the placebo. Histograms displaying the
probability of being a specific category, either SD or PD, are shown for DTI and DSC parameters (left)
and DCE parameters (right). Each half of this figure (left/right) represents the data from
baseline/first mid-treatment differences (left) and differences between the two mid-treatment data
sets (right).
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PR

SD

PD

PR

SD

PD

Figure 5-6. DTI and DSC QIB probability histograms for voxels from patients receiving
bevacizumab. Histograms displaying the distributions of DTI and DSC derived QIB differences
between baseline and the first mid-treatment study (left) and between the first and second midtreatment studies (right)
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PR

SD

PD

PR

SD

PD

Figure 5-7. DCE QIB probability histograms for voxels from patients receiving bevacizumab.
Histograms displaying the distributions of DTI and DSC derived QIB differences between baseline
and the first mid-treatment study (left) and between the first and second mid-treatment studies
(right)
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Probability histograms are another visualization that are perhaps more instructive for assessing
data patterns in the context of ordinal regression, and consist of the probability of an observation
plotted as a function of the individual covariates. Because of the manner in which ordinal regression is
performed, namely that the probability is the dependent variable, these plots can assist in elucidating
the functional form of the covariates (e.g., linear or quadratic), if any exists. Visualization of these
histograms for voxel data from patients receiving the placebo is provided in Figure 5-5. The FA
baseline/mid-treatment difference histograms show an example of data that would be modeled
appropriately with a linear covariate. In this case, increasing differences in FA are associated with an
increased probability of exhibiting SD, and, conversely, decreasing FA values appear to be an indicator of
increasing chances of a voxel belonging to the PD category. Ktrans and vp both exhibit interesting trends in
that the probability for a voxel to be in the PD category increase as the differences in the magnitude of
those parameters becomes different from zero. A second order term would be a likely candidate for
modeling trends of this nature. Similar plots are provided for voxels extracted from patients undergoing
bevacizumab treatment, and are shown in Figure 5-6 and Figure 5-7. Although these data are
substantially noisier compared with patients on the other treatment arm, some potential trends still
exist. For example, changes in rCBV between the baseline and first mid-treatment scan seem to be a
good discriminator between the PR and SD categories, which would likely be most optimal if modeled
with an indicator variable such as

{

,

5.3

as opposed to a continuous variable. The rCBV difference between the two mid-treatment data sets
might be modeled well as the absolute value of the rCBV. Another potential linear trend can be seen in
ve differences from baseline, but such a relationship would provide little information about the SD.
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This qualitative investigation of the data provided substantial incentive to reduce the proposed
ordinal classifier (categories: PR, SD, and PD) to a simple logistic regression model by combining the PR
and SD classes. With this limited data set, a full range of responses was not exhibited, especially
apparent in the lack of patients exhibiting a partial response. In fact, using an ordinal model with all
voxels in the PR category extracted from a single patient precludes accuracy assessment of that
particular category using LOO cross-validation. In addition, there was little evidence in the probability
histograms that voxels categorized as SD were distinguishable from PR categories. In the clinical setting,
prediction of progressive disease carries substantially more importance than either stable disease or
partial response, as knowledge of progression could potentially inform adaptation treatment regimens.
For these reasons, logistic models were also used to build a classifier for this cohort of patients.

5.4.3

Statistical Classification and Response Maps

Initially, the model proposed in equation 5.1, and all unique combinations of the QIB

Model Parameters Stable Disease Progressive Disease
Overall
R2
ADC
72.9(13.0)
25.3(14.4)
46.8(11.1) 0.040(0.010)
FA
67.3(13.3)
40.0(15.4)
51.3(10.7) 0.060(0.012)
Ktrans
69.7(12.7)
30.9(16.2)
48.8(10.6) 0.046(0.009)
ve
61.9(8.7)
34.3(13.0)
48.2(8.4) 0.12(0.007)
vp
70.6(11.4)
25.5(12.8)
50.8(10.1) 0.054(0.008)
rCBV
52.2(10.2)
43.2(13.8)
45.7(8.5) 0.090(0.010)
ve/rCBV
46.4(6.7)
50.2(13.2)
41.0(5.9) 0.17(0.009)
FA/vp
69.0(11.1)
35.2(11.7)
52.3(9.7) 0.08(0.010)
Table 5-6. Ordinal classifier leave-one-out accuracies for linear, first-order interaction, and
squared terms. This table summarizes the prediction accuracies for the multi-parameter models
exhibiting the highest categorical and overall accuracies. Table cells with a black background and
white text represent the highest accuracy for the respective category, identifying both single and
multi-parameter maximum accuracies.
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parameters, was fitted to the ordinal regression model. Accuracies for these models for all combinations
of QIBs and LOO patient data sets were computed, noting that patient 4 was excluded from the ordinal
LOO cross-validation because creation of a training data set incorporating the PR category required the
inclusion of voxel data from this patient. Results from multi-parameter ordinal models with the highest
categorical and overall prediction accuracies, including model accuracies for the corresponding single
parameter models, are summarized in Table 5-6. For the single parameter models, overall accuracies
were approximately 50%, with SD accuracies approaching 70% (except for rCBV) and PD accuracies on
the order of 30% (rCBV is again an exception). Single parameter models incorporating ADC, FA, Ktrans, and
vp were comparable in SD accuracies, but the corresponding PD accuracies were abysmal. Conversely,
rCBV seemed to perform best as a predictor for the PD category with accuracies near 50%. R2 values
(<0.116) suggest that fitted single parameter models were inadequate in improving the fitted models
compared with the null model. Moreover, incorporating multiple QIB parameters did little to improve
either the fits or prediction accuracies with the slight increases in R2 values likely attributed to increasing
the number of model parameters. Although omitted from these tables, the highest R2 value (0.250) was
found to correspond to the model including all QIBs, an unsurprising result consistent with R2 inflation.
Corresponding logistic models were also fit in the same manner as these ordinal models by
combining the PR and SD categories (i.e., no progression, abbreviated as NP) as was motivated by the
observations discussed in the preceding subsection (5.4.3). Accuracies for all single parameter models
and multiple parameter models exhibiting the highest classification prediction accuracies in each of the
two response categories and overall accuracies are tabulated in Table 5-7. Similarly to the ordinal
classifier, minimal variation was observed across the categories of the single parameter models, with
prediction accuracies for NP hovering around 60%, PD approximately 45%, and overall accuracies also
around 60%. In all cases, R2 seemed to indicate that by combining the PR and SD categories the resultant
models better explained the data. Inflation of R2 resulting from over-fitting the data was also observed
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Model Parameters No Progression Progressive Disease
ADC
60.7(15.2)
49.3(17.4)
FA
65.8(13.3)
44.3(14.8)
trans
K
69.3(12.3)
34.9(14.2)
ve
61.5(11.3)
47.3(15.7)
vp
66.2(12.3)
46.8(16.2)
rCBV
57.8(12.2)
47.4(16.3)
ADC/vp
64.0(12.1)
46.4(16.2)
trans
ADC/K
68.7(11.7)
35.4(14.1)
FA/ve/vp/rCBV
58.8(8.4)
53.8(12.7)

Overall
65.2(10.9)
61.2(10.5)
56.4(10.1)
59.2(9.1)
62.7(10.3)
57.4(9.5)
60.8(10.0)
55.5(9.9)
53.9(7.9)

R2
0.11(0.18)
0.13(0.020)
0.12(0.016)
0.15(0.014)
0.13(0.016)
0.17(0.018)
0.14(0.016)
0.12(0.017)
0.28(0.016)

Table 5-7. Logistic classifier leave-one-out accuracies and R2 values for linear, first-order
interaction, and squared terms. This table summarizes the prediction accuracies (standard error)
for the multi-parameter models exhibiting the highest categorical and overall accuracies. Table cells
with a black background and white text represent the highest accuracy for the respective category,
identifying both single and multi-parameter maximum accuracies.

for the logistic regression models where, again, the six QIB model produced the highest R2 (0.314)
averaged over all LOO cases.
While the average cross-validation accuracies for the SD or, in the case of the logistic models, NP
categories seemed promising using a relatively straightforward regression model, those same accuracies
for the PD category appeared disproportionately low. Investigation of individual LOO cases revealed that
accuracies for patient 5, who exhibited only PD, were on the order of 1-2% for logistic and ordinal, and,
interestingly, this is also the patient for whom the exact treatment details were unknown. Incorrect
treatment assignment is one potential cause for these low prediction accuracies. Investigation of the
training accuracies, the accuracy with which the model predicts the correct category for the data used to
generate the model, showed some of the highest overall accuracies, suggesting that patient 5 QIBs were
potentially deleteriously impacting the fitted model. As a quick test, the cross-validation was re-run for
the same model, excluding patient 5 from consideration. The results (not shown here) for the ordinal
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model showed negligible (a few percent) improvements in the overall and SD prediction accuracies, but
decreases in PD accuracies by a factor of two in most cases. Curiously, the R2 values, on average,
increased by a factor of nearly 2 for the models listed in Table 5-6. Similar observations were noted in
the logistic model when performing LOO cross-validation without using patient 5 data. A similar
occurrence of highly skewed accuracies occurs when patient 10 is the LOO case. However, under these
circumstances, the SD (or logistic equivalent, NP) accuracies exhibit abnormally low prediction
accuracies (<30%) that depend heavily on the QIBs used in the model. Other patient data sets (patients 8
and 9), when removed as an LOO case, exhibited low PD prediction accuracies on the order of 10% for
the logistic models, but not the ordinal models. For each of the overall accuracies listed in these tables,
there was a wide range of accuracies for the associated categories.
As discussed in section 5.4.2, the probability of classifying a given voxel in a specific category as
a function of the rCBV differences between baseline and the first mid-treatment imaging study exhibited
behavior more suggestive of a binary response as opposed to a continuous variable. To investigate this
potential improvement in both the ordinal and logistic regression models, LOO was re-run replacing all
instances of rCBV1 in equation 5.1 with an indicator variable; the squared term was excluded from the
model. Resultant ordinal and logistic prediction accuracies exhibited negligible change over the original
model.
Although the prediction accuracies of the models developed in this specific aim were less than
ideal, illustration of the resultant maps for certain combinations of parameters suggests that these
models can potentially detect heterogeneous response. To that end, several axial slices from the
imaging data of patient 8, which included categorization of SD and PD voxels on the same slice, provided
an excellent qualitative example of response heterogeneity. Individual maps were generated for each of
the categories with the values of these color maps representing the probability of a model specific
vector of covariates belonging to the category specified by the map. Figure 5-8 and Figure 5-9 show an
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example slice exhibiting SD (left half of the colored region) and PD (right half of the colored region) as
defined by the oncologist for the ordinal and logistic models, respectively, containing the QIBs ADC, FA,
and rCBV. For the ordinal model, a large “hotspot” was seen on the PR probability map within the area
categorized as SD by the oncologists, indicating, according to the model, an area that will likely exhibit
PR. Similar hotspots were seen in areas of PD on the PD probability map, suggesting correct
categorization. Of the three maps, the SD probability map exhibits a more uniform pattern, categorizing
voxels from both the SD/PD regions as SD. For the logistic model, the combined PR/SD map shows a
relatively large region of high probability extending well into the PD region defined by the oncologists,
consistent with the combined probability maps of the ordinal model. Hotspots similar to those exhibited
by the ordinal models are also seen in the PD probabilities of the logistic PD map. For comparison, the
models producing the best multi-parameter overall accuracies are shown in Figure 5-10 and Figure 5-11
(best ordinal model) and Figure 5-12 and Figure 5-13 (best logistic model). These maps exhibit more
uniform probabilities compared with the maps of Figure 5-8 and Figure 5-9.
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Figure 5-8. Example ordinal regression response category scores. Response category scores for PR
(top left), SD (top right), and PD (bottom) for the ordinal model incorporating ADC, FA, and rCBV.
The left half of the region displayed in color was categorized as SD and the other half as PD.
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Figure 5-9. Example logistic regression response category scores. Response category scores for
PR/SD (left) and PD (right) for the logistic model incorporating ADC, FA, and rCBV. The left half of the
region displayed in color was categorized as SD and the other half as PD.
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Figure 5-10. Example ordinal regression response category scores. Response category scores for PR
(top left), SD (top right), and PD (bottom) for the ordinal model incorporating FA and vp. The left half
of the region displayed in color was categorized as SD and the other half as PD.
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Figure 5-11. Example logistic regression response category scores. Response category scores for
PR/SD (left) and PD (right) for the logistic model incorporating FA and vp. The left half of the region
displayed in color was categorized as SD and the other half as PD.
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Figure 5-12. Example ordinal regression response category scores. Response category scores for
PR/SD (left) and PD (right) for the logistic model incorporating ADC and vp. The left half of the region
displayed in color was categorized as SD and the other half as PD.

144

Figure 5-13. Example logistic regression response category scores. Response category scores for
PR/SD (left) and PD (right) for the logistic model incorporating ADC and vp. The left half of the region
displayed in color was categorized as SD and the other half as PD.

5.5 Discussion
Incorporating multiple quantitative imaging biomarkers into a framework that allows
predictions of treatment response based on radiological response is a promising avenue for the early
detection of treatment response. More importantly, the development and validation of methods for
developing multi-parametric analysis techniques which provide means of preserving the inherent spatial
heterogeneity of underlying disease processes is paramount. The work performed in this specific aim
utilized the software developed in specific aim 2, with confidence that variance introduced by the
analysis tools was below that expected in the QIB treatment related changes, to show that ordinal
regression models could be used to incorporate multiple parameters resulting in maps that provided
predictions of treatment response based on radiological response. Although the accuracy of these
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techniques, estimated in a severely limited data set, was relatively low, the framework has been shown
to generate spatial maps encoding treatment response information.
Perhaps the biggest limitation of this current study, although there are several, is in the very
limited nature of the data sets. Despite the large numbers of voxels that were available for training the
classification models, only 9 patient data sets were suitable for use in generating these ordinal
regression models (10 for the logistic models). This limited number of patients likely resulted in a highly
imprecise and inaccurate estimate of the generalization accuracy. In addition to the limited number of
patients, the limited number of voxels surrounding the surgical cavity that represented original disease
was also very limited. Voxels beyond this region are more difficult to model with DCE PK models because
of the intact, or partially so, BBB, effectively introducing noise into the models (as was shown in the
model validation of specific aim 2). A problem that was further compounded by the low resolution and
poor fits exhibited in the analysis of the DSC data.
Perhaps another limitation of the current study can be found in the definition of response.
Despite the vast experience of the two expert radiation oncologists, misclassifications of voxels at this
level would introduce large variances and potential biases in the trained models. Ideally, validation of
the framework developed herein would require biological correlates such as histopathology samples,
which could potentially be guided by these response maps. For example, patient 5 exhibited prediction
accuracies on the order of 1-2% for a large number of voxels (~2500) if these voxels were assumed to
correspond to PD. If in fact, these voxels represented should have been classified as SD, the model might
be heavily biased toward classifying SD voxels as PD. Thus, the lack of “ground truth” data makes the
clinical interpretation of these response maps difficult, if not impossible, but this framework, with
further validation of QIBs and the models used to amalgamate those parameters may potentially
introduce meaningful clinical information, possibly to the extent of informing the adaptation of
ineffective treatments.
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Chapter 6 Conclusions and Future Directions

As discussed at length in Chapter 1, quantitative MR imaging biomarkers are becoming
increasingly incorporated into early phase clinical trials as a means of non-invasively assessing treatment
response and the associated heterogeneity inherent in those responses. Substantial evidence exists to
support the investigation of numerous promising applications for utilizing these QIBs as a means of
assessing treatment response. Moreover, the increasing complexity of anticancer therapies and
associated heterogeneity in tissue responses necessitates tools capable of detecting locoregional
treatment associated changes. Incorporation of multiple complimentary QIBs can potentially elucidate
these spatially heterogeneous treatment associated changes, potentially guiding clinical decisions, if
incorporated into a classification model. The goal of this work was to address investigate ordinal
regression as a classification method for incorporating multiple QIBs on a voxel-by-voxel basis.

6.1 Evaluation of the Hypothesis
The hypothesis of this work was that by incorporating multiple quantitative imaging biomarkers
into an ordinal regression model, better prediction of locoregional radiological response in post-surgical
glioblastoma patients treated with intensity-modulated radiation therapy and/or bevacizumab would
result compared with the response predicted by a single quantitative imaging biomarker. Three specific
aims were developed and completed to provide an assessment of the individual framework components
(i.e., equipment and analysis methods) and to generate response maps allowing evaluation of the
central hypothesis.
Development of quality control phantoms and ongoing acquisitions to assess and mitigate
equipment bias and variance was the focus of specific aim 1. Two phantoms were developed: a multiple

147

compartment phantom with a range of R1 values for assessing DCE acquisitions and a multiple
compartment phantom with multiple ADC values for assessing diffusion acquisitions (DWI and DTI). As
discussed in Chapter 3, longitudinal variance, and even biases associated with measurements made
away from isocenter, equipment level variance is well below the level of expected changes associated
with in vivo QIB measurements. These results suggest that equipment related sources of bias and
variance will minimally impact models developed to account for longitudinal changes in vivo.
Specific aim 2 focused on the development and validation of a comprehensive software package
for both modeling quantitative MR acquisitions and incorporating the resultant QIBs into an ordinal
regression analysis. The Quantitative Utility for Assessment of TreaTment RespOnse (QUATTRO) was
developed, featuring advanced programming and graphical user interfaces. Object oriented
programming principles were employed to handle the numerous bookkeeping tasks such as importing,
storing, and manipulating images, ROIs, and treatment planning information with support for a number
of common data storage formats (e.g., DICOM 3.0, Pinnacle, and Analyze). Included in this software
package are a collection of classes for performing modeling of common quantitative MR imaging
acquisition strategies and specific interfaces for modeling longitudinal data in the context of treatment
response. Furthermore, these quantitative modeling tools were validated with digital reference objects
encompassing a range of model parameter space matched to expected in vivo values and over a range
of acquisition parameters and noise levels. As with the results of specific aim 1, the software validation
steps suggested levels of variance well below the anticipated changes resulting from treatment.
Work performed in specific aim 2 provided a means of programmatically calculating QIBs, coregistering resultant QIB maps, extracting QIB parameters from patient data sets on which response was
defined, and generating ordinal regression models used for classification. These tasks (or more
succinctly, the generation of response maps) were the goal of specific aim 3. By performing leave-oneout cross-validation, an estimate, albeit a very preliminary estimate, of the generalization error for the

148

trained ordinal (and logistic) classifiers was attained. Little, if any, distinction was found between those
multi-parametric models with the highest accuracies and the corresponding single parameter models,
let alone statistically significant differences.
Unfortunately, the proposed hypothesis was not supported by the data collected and analyzed
in this work. In large part, this lack of support likely stems from the very limited data set that was
retrospectively analyzed, with only 9 (10 for logistic models) patient data sets for developing and
assessing the ordinal regression models. Of these data sets, an insufficient number of partial response
data prevented assessing the classification accuracies for the PR category, and concentrated data
distributions (e.g., patient 8) as discussed in chapter 5 may have deleteriously impacted the training of
regression models during the LOO process, resulting in an underestimation of the generalization
prediction accuracies. Another potential confounding factor is the absence of ground truth data. Some
of the voxels categorized as SD may, in actuality, be exhibiting partial response or progressive disease,
and similarly for other categories. Limitations of the routine clinical imaging used to assess treatment
response are likely central to these initial misclassifications, which would effectively obscure detectable
trends in QIBs across the response categories.
Although the hypothesis was not confirmed, the work performed to address this hypothesis
resulted in a number of substantiative and novel contributions. Phantoms and associated acquisition
protocols were developed for brain applications, demonstrating the ability to longitudinally monitor
equipment related sources of bias and variance in relation to diffusion and DCE QIBs. A comprehensive
software package, QUATTRO, was designed and implemented in the MATLAB programming
environment providing all necessary tools for perform voxel-by-voxel assessments of response to
anticancer therapies using multiple QIB. More generally, a methodology for incorporating multiple QIBs,
not limited to quantitative MRI acquisitions, into an ordinal regression classifier was developed.
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6.2 Future Directions
Although self-evident, the acquisition of quality control data that provides a means of assessing
equipment related bias and variance should be ongoing. One notably flaw in the work performed in
specific aim 1 is the lack of DSC acquisition assessments. Future studies should incorporate, in addition
to the diffusion and DCE acquisitions, an additional assessment of DSC parameter reproducibility. Like
the DCE QIBs, those derived from DSC data are incapable of being measured using a static phantom.
However, by measuring the signal stability with the DCE phantom designed in this study using a T2- or
T2*-weighted dynamic scan, simulations similar to the PK simulations could be performed to assess rCBV
reproducibility. In addition to incorporating an assessment of DSC derived QIBs, a more thorough
assessment of external stimuli such as temperature could potentially provide a means of correcting
quantitative measurements for experimental conditions to better assess equipment bias and variance.
To that end, assessments of bias and variance might be potentially improved by better characterizing
design parameters, allowing better estimates of expected measurement quantities. This is particularly
true for the ADC phantom, as the ADC values used to design the phantom were crudely estimated from
previously published data.
With regard to the phantom studies, another interesting avenue of investigation is to determine
the frequency with which these acquisitions should be performed, as weekly phantom studies can
become quite time consuming. Moreover, at institutions with other ongoing quality control procedures
in place that occur with some frequency, for example the daily quality control that is performed M.D.
Anderson Cancer Center, complimentary or surrogate information derived from these acquisitions
might provide a means of reducing the frequency of quantitative acquisitions.
Because of the developmental nature of this project and the limited patient cohort used for
testing, many of the tools developed herein represent relatively rudimentary techniques. For example,
the image registration implemented in QUATTRO as a link through the ITK libraries performs
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straightforward rigid registration. Under normal circumstances, the rigidity of the brain with respect to
head movements (or in the case of longitudinal studies, patient setup inaccuracies) allows very
reasonable registration of images using only rigid transformations. However, the cohort used in this
consisted of post-surgical patients, in which small tissue deformations were easily observed. Moving
forward, these small deformations might be accounted for through the implementation of a deformable
image registration tool. For studies investigating extracranial applications, such deformable techniques
become an absolute necessity.
Other tools, such as the quantitative image modeling, might benefit from more advanced
developments. For example, the DCE module of QUATTRO, which uses a standard least squares fitting
routine, performed well when applied to the pharmacokinetic DRO. However, as was observed in the
analysis of patient data sets, a number of suspiciously large values for the parameter ve were found.
Several techniques that have shown promise in improving the fitting of DCE-MRI data are the Bayesian
methods proposed by Schmid et al. [201], the use of Gaussian Process inference as proposed by Wang et
al. [202], or the incorporation of a spatial model [203]. Interestingly, the work performed by Kelm and
Menze [203] provided an example fit in which the model was also unidentifiable, the same issue that
plagued the analysis of patient data. Although DCE data sets were used as an example in this discussion,
these methods could presumably be used for any of the other supported quantitative image models.
Potential model improvements also extend to the classifier developed in the last specific aim of
this work. Specifically, a prominent source of bias and variance exists in the uncertainties associated
with expert readers. Initial development of the models presented in this work relied solely on consensus
data defined between two expert observers. The responses defined in this manner were taken as the
“true” response, but the introduction of a second observer, or multiple observers, for that matter,
would very likely produce different results. In the context of ordinal models, a multi-rater model can be
developed to estimate the variance associated with a group expert readers. While this is useful for
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investigating variance associated with individual raters, perhaps more useful is the coupling of such an
analysis with the ordinal regression model. By constructing the regression model in this manner, a
comparison between the variance associated with individual raters and the fitted regression models can
be made. In addition to this more appropriate model, the expected spatial correlations might also be
modeled using a spatial model.
Validation of the framework and models developed herein would ideally involve acquisition of
image guided multi-site biopsies and corresponding histology to confirm the predictions made by these
models. By performing validation in this manner, a large source (expert reader) of variance, and possibly
bias, may be avoided, potentially providing improved model SNR characteristics. In addition to biological
correlates, further performance assessment of these response maps might involve prediction of overall
patient survival (the gold standard for clinical trials).
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